Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
1810009J 06Rik | |
NM_023707 |
RIKEN cDNA 1810009J06 gene (1810009J06Rik), mRNA [NM_023707] |
KLA | .94 |
1.09 |
1.01 |
.98 |
1.05 |
.99 |
1.19 |
| ATP | .96 |
.90 |
.96 |
1.04 |
.99 |
1.07 |
1.05 |
| KLA/ATP | 1.02 |
.98 |
1.01 |
1.09 |
1.08 |
1.06 |
1.01 |
|
2210010C 04Rik | |
NM_023333 |
RIKEN cDNA 2210010C04 gene (2210010C04Rik), mRNA [NM_023333] |
KLA | 1.36 |
1.41 |
1.44 |
1.22 |
1.24 |
1.13 |
1.10 |
| ATP | 1.02 |
.98 |
1.05 |
.96 |
1.01 |
1.02 |
1.06 |
| KLA/ATP | 1.35 |
1.18 |
1.33 |
1.15 |
1.02 |
1.06 |
1.09 |
|
AK082687
| |
AK082687 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230086D05 product:unclassifiable, full insert sequence [AK082687] |
KLA | 1.00 |
.95 |
1.04 |
.95 |
1.01 |
1.01 |
1.14 |
| ATP | 1.00 |
.96 |
1.03 |
1.05 |
.92 |
1.02 |
.89 |
| KLA/ATP | 1.01 |
1.09 |
1.04 |
1.03 |
1.05 |
1.01 |
1.02 |
|
Adcyap1 | |
NM_009625 |
adenylate cyclase activating polypeptide 1 (Adcyap1), mRNA [NM_009625] |
KLA | 1.00 |
1.02 |
.98 |
.99 |
1.01 |
.99 |
.90 |
| ATP | 1.05 |
1.00 |
.93 |
.94 |
.98 |
.96 |
.96 |
| KLA/ATP | .99 |
.97 |
.99 |
.98 |
.92 |
.90 |
.94 |
|
Adcyap1r 1 | |
NM_007407 |
adenylate cyclase activating polypeptide 1 receptor 1 (Adcyap1r1), transcript variant 1, mRNA [NM_007407] |
KLA | 1.03 |
1.02 |
.99 |
1.03 |
1.02 |
1.02 |
1.05 |
| ATP | 1.03 |
1.01 |
1.14 |
1.01 |
.99 |
1.02 |
1.01 |
| KLA/ATP | .97 |
.99 |
1.03 |
1.08 |
1.04 |
1.04 |
.98 |
|
Adora1 | |
NM_001008533 |
adenosine A1 receptor (Adora1), transcript variant 1, mRNA [NM_001008533] |
KLA | 1.01 |
1.03 |
.94 |
1.00 |
1.01 |
1.11 |
1.13 |
| ATP | .99 |
1.02 |
1.06 |
1.05 |
1.07 |
1.02 |
1.16 |
| KLA/ATP | 1.05 |
.99 |
1.02 |
1.04 |
1.05 |
1.11 |
1.09 |
|
Adora2a | |
NM_009630 |
adenosine A2a receptor (Adora2a), mRNA [NM_009630] |
KLA | 9.23 |
9.88 |
9.08 |
9.21 |
9.36 |
7.45 |
8.23 |
| ATP | 1.09 |
1.01 |
1.36 |
2.05 |
4.26 |
8.29 |
1.91 |
| KLA/ATP | 9.17 |
11.00 |
9.06 |
9.28 |
10.88 |
11.46 |
9.73 |
|
Adora2b | |
NM_007413 |
adenosine A2b receptor (Adora2b), mRNA [NM_007413] |
KLA | 2.50 |
3.09 |
4.71 |
7.11 |
7.38 |
4.18 |
3.17 |
| ATP | .98 |
1.02 |
1.16 |
4.52 |
8.81 |
7.95 |
2.66 |
| KLA/ATP | 2.56 |
3.38 |
4.49 |
5.78 |
7.34 |
7.41 |
6.23 |
|
Adora3 | |
AK013534 |
adult male hippocampus cDNA, RIKEN full-length enriched library, clone:2900016D13 product:A3 ADENOSINE RECEPTOR, full insert sequence [AK013534] |
KLA | 1.66 |
1.76 |
2.92 |
3.13 |
3.41 |
2.11 |
1.40 |
| ATP | 1.16 |
1.07 |
1.11 |
1.04 |
1.05 |
1.33 |
1.56 |
| KLA/ATP | 1.91 |
1.85 |
1.84 |
1.66 |
1.33 |
1.36 |
1.34 |
|
Adora3 | |
NM_009631 |
adenosine A3 receptor (Adora3), transcript variant 1, mRNA [NM_009631] |
KLA | 1.54 |
1.63 |
2.45 |
2.54 |
2.96 |
2.32 |
1.49 |
| ATP | 1.04 |
1.02 |
1.15 |
1.19 |
1.07 |
1.52 |
2.16 |
| KLA/ATP | 1.70 |
1.64 |
1.59 |
1.55 |
1.28 |
1.96 |
2.06 |
|
Adora3 | |
NM_027025 |
adenosine A3 receptor (Adora3), transcript variant 2, mRNA [NM_027025] |
KLA | 1.00 |
1.05 |
1.10 |
1.06 |
1.08 |
1.10 |
1.00 |
| ATP | 1.01 |
1.08 |
1.04 |
1.09 |
.98 |
1.07 |
1.17 |
| KLA/ATP | 1.12 |
1.02 |
1.00 |
1.00 |
.99 |
1.15 |
1.10 |
|
Adra1a | |
NM_013461 |
adrenergic receptor, alpha 1a (Adra1a), mRNA [NM_013461] |
KLA | .78 |
.74 |
.75 |
.85 |
.96 |
1.37 |
2.70 |
| ATP | 1.05 |
1.14 |
.97 |
.97 |
1.69 |
1.06 |
2.56 |
| KLA/ATP | .76 |
.75 |
.83 |
.84 |
1.51 |
1.34 |
4.08 |
|
Adra1b | |
NM_007416 |
adrenergic receptor, alpha 1b (Adra1b), mRNA [NM_007416] |
KLA | 1.04 |
.99 |
.98 |
1.02 |
.99 |
1.00 |
1.01 |
| ATP | 1.00 |
.99 |
.98 |
1.01 |
1.06 |
1.01 |
1.05 |
| KLA/ATP | .99 |
.97 |
1.03 |
1.03 |
1.00 |
.97 |
1.08 |
|
Adra1d | |
NM_013460 |
adrenergic receptor, alpha 1d (Adra1d), mRNA [NM_013460] |
KLA | 1.13 |
1.12 |
1.21 |
1.25 |
1.30 |
1.34 |
1.27 |
| ATP | 1.02 |
.99 |
1.16 |
1.08 |
1.13 |
1.11 |
1.06 |
| KLA/ATP | 1.15 |
1.10 |
1.20 |
1.14 |
1.24 |
1.16 |
1.13 |
|
Adra2a | |
NM_007417 |
adrenergic receptor, alpha 2a (Adra2a), mRNA [NM_007417] |
KLA | 1.00 |
.92 |
.97 |
.98 |
.93 |
.97 |
.95 |
| ATP | 1.00 |
.98 |
1.07 |
1.36 |
1.19 |
1.23 |
1.06 |
| KLA/ATP | .94 |
.98 |
1.01 |
1.20 |
1.25 |
1.16 |
1.03 |
|
Adra2b | |
NM_009633 |
adrenergic receptor, alpha 2b (Adra2b), mRNA [NM_009633] |
KLA | .94 |
1.00 |
1.08 |
1.00 |
1.03 |
.94 |
1.05 |
| ATP | .95 |
1.00 |
1.01 |
.98 |
.94 |
1.11 |
1.10 |
| KLA/ATP | .99 |
1.14 |
1.10 |
1.05 |
1.01 |
1.09 |
1.10 |
|
Adra2c | |
NM_007418 |
adrenergic receptor, alpha 2c (Adra2c), mRNA [NM_007418] |
KLA | 1.04 |
.99 |
.96 |
1.08 |
.95 |
1.01 |
.99 |
| ATP | 1.02 |
.99 |
.98 |
1.03 |
1.01 |
.97 |
.91 |
| KLA/ATP | 1.05 |
.98 |
.97 |
.96 |
.95 |
1.00 |
1.07 |
|
Adrb1 | |
NM_007419 |
adrenergic receptor, beta 1 (Adrb1), mRNA [NM_007419] |
KLA | .88 |
.86 |
.88 |
.86 |
.87 |
.87 |
.87 |
| ATP | .97 |
.97 |
.95 |
.89 |
.89 |
.90 |
.87 |
| KLA/ATP | .90 |
.88 |
.91 |
.84 |
.91 |
.79 |
.82 |
|
Adrb2 | |
NM_007420 |
adrenergic receptor, beta 2 (Adrb2), mRNA [NM_007420] |
KLA | .28 |
.26 |
.32 |
.31 |
.34 |
.31 |
.29 |
| ATP | 2.09 |
2.43 |
2.74 |
1.72 |
.96 |
.63 |
.29 |
| KLA/ATP | .28 |
.29 |
.52 |
.69 |
.65 |
.35 |
.23 |
|
Agrp | |
NM_007427 |
agouti related protein (Agrp), mRNA [NM_007427] |
KLA | 1.03 |
.96 |
1.01 |
.99 |
1.02 |
.97 |
1.01 |
| ATP | 1.00 |
1.03 |
.99 |
.99 |
.97 |
.97 |
.94 |
| KLA/ATP | .94 |
.98 |
1.00 |
.94 |
.94 |
.93 |
.97 |
|
Agtr1a | |
NM_177322 |
angiotensin II receptor, type 1a (Agtr1a), mRNA [NM_177322] |
KLA | 1.04 |
1.00 |
1.00 |
1.03 |
1.03 |
.95 |
1.00 |
| ATP | .98 |
.99 |
1.00 |
1.00 |
.95 |
1.05 |
1.06 |
| KLA/ATP | 1.00 |
.97 |
1.03 |
.97 |
.99 |
.96 |
.98 |
|
Agtr1b | |
NM_175086 |
angiotensin II receptor, type 1b (Agtr1b), mRNA [NM_175086] |
KLA | 1.02 |
.94 |
1.04 |
1.01 |
1.01 |
1.00 |
.95 |
| ATP | .97 |
1.01 |
1.03 |
.95 |
.98 |
1.09 |
1.02 |
| KLA/ATP | .94 |
.99 |
.99 |
.97 |
.99 |
.95 |
1.12 |
|
Agtr2 | |
NM_007429 |
angiotensin II receptor, type 2 (Agtr2), mRNA [NM_007429] |
KLA | .99 |
.93 |
1.00 |
.98 |
.98 |
1.03 |
.96 |
| ATP | 1.03 |
1.10 |
1.02 |
1.01 |
.91 |
1.03 |
1.01 |
| KLA/ATP | .93 |
.95 |
1.01 |
.99 |
1.00 |
.95 |
.99 |
|
Agtrl1 | |
NM_011784 |
angiotensin receptor-like 1 (Agtrl1), mRNA [NM_011784] |
KLA | 1.01 |
1.06 |
1.08 |
1.16 |
1.14 |
1.13 |
1.02 |
| ATP | .98 |
1.13 |
1.08 |
.93 |
1.00 |
1.10 |
1.13 |
| KLA/ATP | .98 |
.97 |
1.22 |
1.09 |
1.04 |
1.15 |
1.09 |
|
Apln | |
NM_013912 |
apelin (Apln), mRNA [NM_013912] |
KLA | 1.11 |
1.12 |
1.19 |
1.18 |
1.27 |
1.26 |
1.19 |
| ATP | 1.04 |
1.00 |
1.08 |
1.03 |
.98 |
.93 |
1.03 |
| KLA/ATP | 1.11 |
1.13 |
1.17 |
1.14 |
1.08 |
.99 |
1.13 |
|
Avp | |
NM_009732 |
arginine vasopressin (Avp), mRNA [NM_009732] |
KLA | .98 |
.99 |
1.04 |
1.02 |
1.03 |
1.09 |
1.05 |
| ATP | 1.02 |
1.06 |
1.03 |
.99 |
1.01 |
1.01 |
1.08 |
| KLA/ATP | 1.00 |
1.02 |
1.10 |
1.01 |
.99 |
1.02 |
1.02 |
|
Avpr1a | |
NM_016847 |
arginine vasopressin receptor 1A (Avpr1a), mRNA [NM_016847] |
KLA | 1.00 |
1.07 |
.95 |
.99 |
1.01 |
1.01 |
1.00 |
| ATP | .99 |
.94 |
1.01 |
1.08 |
1.01 |
1.06 |
.99 |
| KLA/ATP | 1.10 |
.98 |
1.04 |
1.00 |
.99 |
1.05 |
1.00 |
|
Avpr1b | |
NM_011924 |
arginine vasopressin receptor 1B (Avpr1b), mRNA [NM_011924] |
KLA | 1.01 |
.93 |
.97 |
1.03 |
1.00 |
.97 |
1.01 |
| ATP | .99 |
1.02 |
1.05 |
1.03 |
1.01 |
1.04 |
1.06 |
| KLA/ATP | .93 |
1.00 |
.97 |
.97 |
.92 |
.96 |
1.04 |
|
Avpr2 | |
NM_019404 |
arginine vasopressin receptor 2 (Avpr2), mRNA [NM_019404] |
KLA | .98 |
1.00 |
.99 |
1.01 |
.98 |
1.05 |
.95 |
| ATP | .99 |
1.00 |
1.02 |
1.01 |
1.01 |
1.05 |
1.01 |
| KLA/ATP | 1.00 |
.98 |
1.02 |
.98 |
.98 |
1.01 |
1.02 |
|
Bdkrb1 | |
NM_007539 |
bradykinin receptor, beta 1 (Bdkrb1), mRNA [NM_007539] |
KLA | 1.60 |
1.44 |
1.47 |
1.36 |
1.29 |
1.38 |
1.04 |
| ATP | 1.05 |
.99 |
1.17 |
1.12 |
1.15 |
1.16 |
.95 |
| KLA/ATP | 1.51 |
1.59 |
1.94 |
1.30 |
1.22 |
1.23 |
1.20 |
|
Bdkrb2 | |
NM_009747 |
bradykinin receptor, beta 2 (Bdkrb2), mRNA [NM_009747] |
KLA | .97 |
.96 |
1.01 |
1.09 |
1.01 |
1.00 |
1.08 |
| ATP | 1.07 |
.98 |
1.04 |
1.01 |
1.05 |
1.00 |
1.08 |
| KLA/ATP | 1.02 |
1.05 |
1.04 |
1.01 |
1.03 |
1.04 |
.98 |
|
Brs3 | |
NM_009766 |
bombesin-like receptor 3 (Brs3), mRNA [NM_009766] |
KLA | 1.01 |
1.02 |
1.04 |
.99 |
1.04 |
.99 |
.98 |
| ATP | .98 |
1.08 |
.99 |
.94 |
.96 |
1.04 |
.96 |
| KLA/ATP | .94 |
.96 |
1.02 |
.99 |
.95 |
.95 |
1.06 |
|
C3ar1 | |
NM_009779 |
complement component 3a receptor 1 (C3ar1), mRNA [NM_009779] |
KLA | .93 |
1.01 |
1.03 |
1.20 |
1.34 |
1.60 |
1.59 |
| ATP | 1.03 |
1.13 |
.81 |
.99 |
.72 |
.48 |
1.44 |
| KLA/ATP | 1.06 |
1.02 |
.77 |
.99 |
.81 |
.85 |
1.20 |
|
C5ar1 | |
NM_007577 |
complement component 5a receptor 1 (C5ar1), mRNA [NM_007577] |
KLA | 1.10 |
1.18 |
1.09 |
.81 |
.64 |
.49 |
.83 |
| ATP | 1.07 |
1.30 |
1.02 |
2.07 |
.92 |
.48 |
1.75 |
| KLA/ATP | 1.24 |
1.32 |
.83 |
1.58 |
.69 |
.46 |
.85 |
|
Calcr | |
NM_007588 |
calcitonin receptor (Calcr), transcript variant a, mRNA [NM_007588] |
KLA | .98 |
1.01 |
1.05 |
1.03 |
1.06 |
1.12 |
1.06 |
| ATP | .99 |
.97 |
1.01 |
1.05 |
1.00 |
1.00 |
1.02 |
| KLA/ATP | 1.02 |
1.02 |
.95 |
1.00 |
1.02 |
1.04 |
1.02 |
|
Calcrl | |
NM_018782 |
calcitonin receptor-like (Calcrl), mRNA [NM_018782] |
KLA | 3.33 |
3.29 |
2.57 |
2.69 |
1.56 |
.90 |
1.22 |
| ATP | .93 |
.86 |
.80 |
.77 |
.85 |
1.39 |
.79 |
| KLA/ATP | 2.95 |
2.86 |
1.96 |
1.75 |
1.26 |
.78 |
.79 |
|
Cck | |
NM_031161 |
cholecystokinin (Cck), mRNA [NM_031161] |
KLA | .96 |
1.11 |
.98 |
.99 |
.91 |
1.00 |
1.10 |
| ATP | 1.00 |
1.00 |
1.03 |
1.13 |
1.02 |
1.17 |
2.72 |
| KLA/ATP | 1.08 |
1.00 |
.91 |
1.06 |
1.04 |
1.07 |
1.38 |
|
Cckar | |
NM_009827 |
cholecystokinin A receptor (Cckar), mRNA [NM_009827] |
KLA | 1.00 |
.97 |
1.05 |
1.07 |
.99 |
1.08 |
1.03 |
| ATP | 1.08 |
1.00 |
1.10 |
1.07 |
.94 |
1.00 |
.98 |
| KLA/ATP | .99 |
.98 |
.99 |
1.04 |
1.00 |
1.04 |
1.02 |
|
Cckbr | |
NM_007627 |
cholecystokinin B receptor (Cckbr), mRNA [NM_007627] |
KLA | 1.03 |
1.01 |
1.07 |
1.05 |
1.01 |
1.11 |
1.03 |
| ATP | .94 |
1.04 |
1.04 |
.97 |
1.01 |
1.05 |
1.02 |
| KLA/ATP | 1.03 |
.99 |
1.03 |
1.02 |
1.01 |
1.06 |
1.04 |
|
Cga | |
NM_009889 |
glycoprotein hormones, alpha subunit (Cga), mRNA [NM_009889] |
KLA | .98 |
.95 |
.95 |
1.01 |
1.01 |
.95 |
1.01 |
| ATP | .96 |
.89 |
.84 |
.90 |
1.03 |
.88 |
.98 |
| KLA/ATP | .99 |
.98 |
.83 |
.89 |
.98 |
.91 |
.86 |
|
Chrm1 | |
NM_001112697 |
cholinergic receptor, muscarinic 1, CNS (Chrm1), transcript variant 1, mRNA [NM_001112697] |
KLA | 1.12 |
.99 |
.97 |
1.09 |
.92 |
.91 |
.97 |
| ATP | .95 |
1.06 |
1.01 |
1.06 |
1.05 |
1.06 |
.99 |
| KLA/ATP | 1.00 |
.99 |
1.02 |
1.00 |
1.05 |
.95 |
1.01 |
|
Chrm2 | |
NM_203491 |
cholinergic receptor, muscarinic 2, cardiac (Chrm2), mRNA [NM_203491] |
KLA | 1.03 |
1.05 |
.98 |
1.02 |
1.04 |
1.06 |
1.05 |
| ATP | 1.09 |
.94 |
1.08 |
1.06 |
.98 |
1.04 |
.97 |
| KLA/ATP | 1.01 |
1.05 |
.97 |
1.01 |
.98 |
1.07 |
.99 |
|
Chrm3 | |
AK051841 |
12 days embryo eyeball cDNA, RIKEN full-length enriched library, clone:D230008K23 product:unclassifiable, full insert sequence. [AK051841] |
KLA | .92 |
.97 |
1.02 |
1.05 |
.96 |
.99 |
1.00 |
| ATP | 1.00 |
.99 |
.99 |
.95 |
1.05 |
1.02 |
1.01 |
| KLA/ATP | .91 |
.98 |
1.06 |
1.07 |
.94 |
1.00 |
.94 |
|
Chrm3 | |
NM_033269 |
cholinergic receptor, muscarinic 3, cardiac (Chrm3), mRNA [NM_033269] |
KLA | .91 |
.99 |
.98 |
.93 |
1.08 |
1.01 |
1.06 |
| ATP | .97 |
1.05 |
1.03 |
.95 |
.99 |
1.01 |
1.10 |
| KLA/ATP | 1.05 |
1.09 |
.99 |
1.00 |
.98 |
1.03 |
1.00 |
|
Chrm4 | |
NM_007699 |
cholinergic receptor, muscarinic 4 (Chrm4), mRNA [NM_007699] |
KLA | .95 |
1.01 |
.97 |
.97 |
.96 |
1.07 |
1.04 |
| ATP | 1.08 |
1.01 |
1.04 |
1.08 |
1.01 |
.99 |
.98 |
| KLA/ATP | 1.01 |
1.04 |
1.04 |
.99 |
.99 |
.96 |
.99 |
|
Chrm5 | |
NM_205783 |
cholinergic receptor, muscarinic 5 (Chrm5), mRNA [NM_205783] |
KLA | .98 |
1.02 |
.96 |
.98 |
1.03 |
1.02 |
1.02 |
| ATP | 1.02 |
.96 |
.96 |
1.15 |
1.00 |
1.06 |
1.04 |
| KLA/ATP | 1.02 |
.90 |
.95 |
1.05 |
1.04 |
1.05 |
.95 |
|
Chrna1 | |
NM_007389 |
cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) (Chrna1), mRNA [NM_007389] |
KLA | .98 |
1.00 |
1.04 |
.97 |
.99 |
.98 |
1.02 |
| ATP | .95 |
.97 |
1.00 |
1.01 |
1.01 |
1.04 |
1.11 |
| KLA/ATP | .96 |
.98 |
1.00 |
1.01 |
.97 |
.99 |
.97 |
|
Chrna10 | |
NM_001081424 |
cholinergic receptor, nicotinic, alpha polypeptide 10 (Chrna10), mRNA [NM_001081424] |
KLA | .95 |
1.04 |
1.03 |
1.04 |
.94 |
.99 |
.97 |
| ATP | 1.03 |
1.00 |
1.03 |
1.03 |
1.04 |
.97 |
1.02 |
| KLA/ATP | 1.03 |
1.03 |
1.07 |
1.01 |
.96 |
1.01 |
1.03 |
|
Chrna2 | |
NM_144803 |
cholinergic receptor, nicotinic, alpha polypeptide 2 (neuronal) (Chrna2), mRNA [NM_144803] |
KLA | 1.01 |
.97 |
.96 |
1.08 |
.99 |
.97 |
1.12 |
| ATP | 1.03 |
1.00 |
.92 |
1.01 |
.99 |
.92 |
1.07 |
| KLA/ATP | 1.06 |
.99 |
1.00 |
1.04 |
.98 |
.93 |
.88 |
|
Chrna3 | |
NM_145129 |
cholinergic receptor, nicotinic, alpha polypeptide 3 (Chrna3), mRNA [NM_145129] |
KLA | 1.03 |
1.04 |
1.00 |
1.03 |
1.08 |
1.04 |
.99 |
| ATP | .98 |
.95 |
.97 |
1.02 |
1.04 |
1.02 |
.99 |
| KLA/ATP | .99 |
.99 |
1.02 |
1.04 |
1.07 |
.99 |
1.02 |
|
Chrna4 | |
NM_015730 |
cholinergic receptor, nicotinic, alpha polypeptide 4 (Chrna4), mRNA [NM_015730] |
KLA | .99 |
.96 |
1.01 |
1.01 |
1.00 |
.98 |
.96 |
| ATP | 1.02 |
.98 |
.97 |
1.04 |
.94 |
.96 |
.94 |
| KLA/ATP | .97 |
.99 |
1.00 |
.98 |
1.00 |
.98 |
.98 |
|
Chrna5 | |
NM_176844 |
cholinergic receptor, nicotinic, alpha polypeptide 5 (Chrna5), mRNA [NM_176844] |
KLA | 1.67 |
2.23 |
3.03 |
2.92 |
2.92 |
1.70 |
1.09 |
| ATP | 1.03 |
1.05 |
1.14 |
1.03 |
.96 |
1.06 |
1.04 |
| KLA/ATP | 1.91 |
2.14 |
1.97 |
2.05 |
1.46 |
1.48 |
1.18 |
|
Chrna6 | |
NM_021369 |
cholinergic receptor, nicotinic, alpha polypeptide 6 (Chrna6), mRNA [NM_021369] |
KLA | 1.05 |
.98 |
1.00 |
.93 |
1.05 |
.98 |
.96 |
| ATP | .99 |
.93 |
.98 |
.99 |
.92 |
.95 |
1.01 |
| KLA/ATP | 1.00 |
1.00 |
1.02 |
.93 |
.96 |
.94 |
1.05 |
|
Chrna7 | |
NM_007390 |
cholinergic receptor, nicotinic, alpha polypeptide 7 (Chrna7), mRNA [NM_007390] |
KLA | 1.01 |
.99 |
1.04 |
.96 |
.99 |
.99 |
1.01 |
| ATP | .99 |
.97 |
1.00 |
1.00 |
.99 |
1.04 |
1.00 |
| KLA/ATP | .98 |
1.02 |
1.04 |
.99 |
.95 |
.96 |
1.07 |
|
Chrna9 | |
NM_001081104 |
cholinergic receptor, nicotinic, alpha polypeptide 9 (Chrna9), mRNA [NM_001081104] |
KLA | 1.06 |
1.07 |
1.05 |
1.01 |
.99 |
1.01 |
.94 |
| ATP | .97 |
1.01 |
1.05 |
1.03 |
1.00 |
1.08 |
.99 |
| KLA/ATP | 1.01 |
1.04 |
1.15 |
1.02 |
1.08 |
1.15 |
1.05 |
|
Chrnb1 | |
NM_009601 |
cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) (Chrnb1), mRNA [NM_009601] |
KLA | .90 |
.97 |
.96 |
1.00 |
.95 |
.91 |
.98 |
| ATP | 1.03 |
1.00 |
.91 |
1.02 |
.96 |
.98 |
.93 |
| KLA/ATP | 1.00 |
.96 |
.97 |
.92 |
.94 |
.93 |
.90 |
|
Chrnb2 | |
NM_009602 |
cholinergic receptor, nicotinic, beta polypeptide 2 (neuronal) (Chrnb2), mRNA [NM_009602] |
KLA | .89 |
.85 |
.89 |
.88 |
.78 |
.97 |
.93 |
| ATP | 1.03 |
.99 |
1.36 |
2.35 |
1.30 |
.97 |
.86 |
| KLA/ATP | .86 |
.91 |
.80 |
1.23 |
1.14 |
1.03 |
1.02 |
|
Chrnb3 | |
NM_027454 |
cholinergic receptor, nicotinic, beta polypeptide 3 (Chrnb3), transcript variant 2, mRNA [NM_027454] |
KLA | .95 |
1.00 |
1.02 |
1.02 |
1.05 |
.98 |
1.11 |
| ATP | .98 |
.95 |
1.04 |
1.04 |
1.07 |
.98 |
1.00 |
| KLA/ATP | .92 |
1.09 |
.92 |
1.05 |
.91 |
1.07 |
.95 |
|
Chrnb3 | |
NM_173212 |
cholinergic receptor, nicotinic, beta polypeptide 3 (Chrnb3), transcript variant 1, mRNA [NM_173212] |
KLA | .98 |
1.00 |
.99 |
.95 |
1.01 |
.99 |
.98 |
| ATP | 1.01 |
1.00 |
.98 |
.98 |
1.02 |
.96 |
1.06 |
| KLA/ATP | .99 |
1.00 |
1.01 |
1.04 |
1.01 |
1.02 |
1.13 |
|
Chrnb4 | |
NM_148944 |
cholinergic receptor, nicotinic, beta polypeptide 4 (Chrnb4), mRNA [NM_148944] |
KLA | 1.01 |
1.04 |
.94 |
1.00 |
1.01 |
.96 |
.98 |
| ATP | .97 |
1.00 |
.98 |
.98 |
1.01 |
1.05 |
1.00 |
| KLA/ATP | .95 |
.99 |
1.06 |
.97 |
.98 |
.99 |
1.04 |
|
Chrnd | |
NM_021600 |
cholinergic receptor, nicotinic, delta polypeptide (Chrnd), mRNA [NM_021600] |
KLA | 1.02 |
.92 |
1.09 |
1.02 |
.97 |
1.00 |
1.08 |
| ATP | .98 |
1.06 |
.96 |
1.02 |
1.05 |
1.13 |
1.02 |
| KLA/ATP | 1.02 |
1.02 |
1.02 |
.96 |
1.03 |
1.07 |
1.02 |
|
Chrne | |
NM_009603 |
cholinergic receptor, nicotinic, epsilon polypeptide (Chrne), mRNA [NM_009603] |
KLA | 1.29 |
1.23 |
1.31 |
1.42 |
1.21 |
1.35 |
1.06 |
| ATP | 1.00 |
1.02 |
1.28 |
1.35 |
1.36 |
1.39 |
1.18 |
| KLA/ATP | 1.31 |
1.43 |
1.65 |
1.55 |
1.62 |
1.87 |
1.51 |
|
Chrng | |
NM_009604 |
cholinergic receptor, nicotinic, gamma polypeptide (Chrng), mRNA [NM_009604] |
KLA | 1.00 |
1.02 |
1.02 |
1.04 |
1.04 |
1.02 |
1.06 |
| ATP | 1.00 |
1.01 |
1.00 |
1.02 |
1.00 |
.99 |
1.00 |
| KLA/ATP | 1.04 |
.99 |
1.01 |
1.01 |
1.03 |
1.03 |
1.02 |
|
Cnr1 | |
NM_007726 |
cannabinoid receptor 1 (brain) (Cnr1), mRNA [NM_007726] |
KLA | .97 |
1.05 |
1.03 |
.96 |
.98 |
1.01 |
.92 |
| ATP | 1.02 |
1.05 |
1.01 |
.92 |
1.06 |
1.04 |
.93 |
| KLA/ATP | 1.00 |
.99 |
.96 |
.96 |
1.00 |
.95 |
.99 |
|
Cnr2 | |
NM_009924 |
cannabinoid receptor 2 (macrophage) (Cnr2), mRNA [NM_009924] |
KLA | .16 |
.16 |
.16 |
.20 |
.17 |
.25 |
.31 |
| ATP | .92 |
1.03 |
.95 |
.81 |
.33 |
.18 |
1.26 |
| KLA/ATP | .15 |
.15 |
.20 |
.22 |
.21 |
.21 |
.44 |
|
Copa | |
NM_009938 |
coatomer protein complex subunit alpha (Copa), mRNA [NM_009938] |
KLA | 1.13 |
1.17 |
1.30 |
1.14 |
1.15 |
1.15 |
1.10 |
| ATP | 1.03 |
1.09 |
.98 |
.97 |
.93 |
.88 |
1.02 |
| KLA/ATP | 1.30 |
1.22 |
1.01 |
1.05 |
.88 |
.92 |
.94 |
|
Cort | |
NM_007745 |
cortistatin (Cort), mRNA [NM_007745] |
KLA | 1.02 |
1.05 |
1.01 |
1.05 |
1.08 |
1.03 |
.99 |
| ATP | 1.05 |
1.03 |
1.04 |
1.06 |
.99 |
.98 |
.95 |
| KLA/ATP | 1.11 |
1.07 |
1.16 |
1.08 |
1.04 |
1.06 |
.97 |
|
Crhr1 | |
NM_007762 |
corticotropin releasing hormone receptor 1 (Crhr1), mRNA [NM_007762] |
KLA | 1.00 |
1.05 |
1.06 |
1.05 |
1.06 |
1.06 |
1.05 |
| ATP | 1.04 |
.97 |
1.03 |
1.06 |
1.09 |
1.07 |
1.03 |
| KLA/ATP | 1.08 |
1.10 |
1.05 |
1.11 |
1.10 |
1.05 |
1.13 |
|
Crhr2 | |
NM_009953 |
corticotropin releasing hormone receptor 2 (Crhr2), mRNA [NM_009953] |
KLA | 1.02 |
1.08 |
1.06 |
1.15 |
1.12 |
1.16 |
1.16 |
| ATP | 1.00 |
.99 |
1.22 |
1.12 |
1.22 |
1.22 |
1.22 |
| KLA/ATP | .99 |
1.08 |
1.21 |
1.19 |
1.32 |
1.25 |
1.26 |
|
Ctsg | |
NM_007800 |
cathepsin G (Ctsg), mRNA [NM_007800] |
KLA | 1.15 |
1.23 |
1.36 |
1.24 |
1.14 |
1.09 |
1.22 |
| ATP | .97 |
1.04 |
1.19 |
1.22 |
1.30 |
1.19 |
.98 |
| KLA/ATP | 1.19 |
1.30 |
1.52 |
1.58 |
1.34 |
1.23 |
1.07 |
|
Cysltr1 | |
NM_021476 |
cysteinyl leukotriene receptor 1 (Cysltr1), mRNA [NM_021476] |
KLA | 1.11 |
1.17 |
1.25 |
1.45 |
1.45 |
1.36 |
1.16 |
| ATP | .93 |
.87 |
1.03 |
.83 |
.42 |
.35 |
.71 |
| KLA/ATP | 1.01 |
1.03 |
1.13 |
.95 |
.59 |
.40 |
.61 |
|
Cysltr2 | |
NM_133720 |
cysteinyl leukotriene receptor 2 (Cysltr2), mRNA [NM_133720] |
KLA | 3.09 |
2.91 |
3.56 |
3.38 |
2.86 |
3.71 |
3.63 |
| ATP | 1.00 |
.91 |
1.13 |
.96 |
.77 |
1.04 |
2.02 |
| KLA/ATP | 3.07 |
3.48 |
3.37 |
2.52 |
1.66 |
1.37 |
4.59 |
|
Drd1a | |
NM_010076 |
dopamine receptor D1A (Drd1a), mRNA [NM_010076] |
KLA | .94 |
.99 |
1.02 |
.98 |
.98 |
.99 |
1.06 |
| ATP | 1.07 |
1.03 |
1.01 |
1.08 |
1.08 |
.96 |
1.04 |
| KLA/ATP | 1.04 |
1.00 |
1.01 |
1.06 |
1.08 |
1.06 |
1.09 |
|
Drd2 | |
NM_010077 |
dopamine receptor 2 (Drd2), mRNA [NM_010077] |
KLA | 1.02 |
.98 |
1.03 |
1.09 |
1.07 |
.97 |
1.09 |
| ATP | 1.07 |
1.00 |
.98 |
1.11 |
1.03 |
1.01 |
1.03 |
| KLA/ATP | 1.13 |
1.12 |
1.09 |
1.08 |
1.02 |
1.01 |
1.11 |
|
Drd2 | |
X55674 |
gb|M.musculus mRNA for D2A dopamine receptor [X55674] |
KLA | .95 |
1.00 |
1.06 |
.98 |
.97 |
1.02 |
1.02 |
| ATP | .97 |
.97 |
.99 |
.97 |
.99 |
.97 |
1.01 |
| KLA/ATP | .97 |
1.03 |
.91 |
.90 |
.95 |
.89 |
1.00 |
|
Drd3 | |
NM_007877 |
dopamine receptor 3 (Drd3), mRNA [NM_007877] |
KLA | 1.01 |
1.05 |
.99 |
1.00 |
1.04 |
1.02 |
1.10 |
| ATP | 1.01 |
.92 |
1.08 |
1.08 |
.98 |
.89 |
.97 |
| KLA/ATP | .95 |
1.05 |
.87 |
.95 |
1.09 |
1.06 |
.97 |
|
Drd4 | |
BC051421 |
dopamine receptor 4, mRNA (cDNA clone MGC:58931 IMAGE:6492837), complete cds [BC051421] |
KLA | .98 |
1.04 |
1.01 |
.99 |
.99 |
1.02 |
.98 |
| ATP | 1.00 |
1.00 |
1.00 |
1.03 |
1.01 |
1.03 |
1.04 |
| KLA/ATP | 1.00 |
1.00 |
1.04 |
1.01 |
1.01 |
1.01 |
1.03 |
|
Drd4 | |
NM_007878 |
dopamine receptor 4 (Drd4), mRNA [NM_007878] |
KLA | 1.05 |
1.04 |
1.01 |
.98 |
1.04 |
1.14 |
1.09 |
| ATP | 1.03 |
.99 |
.91 |
.92 |
1.05 |
1.00 |
.99 |
| KLA/ATP | 1.03 |
1.04 |
.97 |
1.00 |
1.03 |
.99 |
1.02 |
|
Drd5 | |
NM_013503 |
dopamine receptor 5 (Drd5), mRNA [NM_013503] |
KLA | 1.00 |
.99 |
.99 |
.93 |
.97 |
1.04 |
1.03 |
| ATP | .99 |
1.00 |
1.00 |
1.01 |
1.01 |
1.02 |
1.00 |
| KLA/ATP | 1.05 |
.95 |
.98 |
1.00 |
.98 |
1.01 |
1.01 |
|
Edg1 | |
NM_007901 |
endothelial differentiation sphingolipid G-protein-coupled receptor 1 (Edg1), mRNA [NM_007901] |
KLA | .08 |
.07 |
.09 |
.11 |
.12 |
.21 |
.35 |
| ATP | 1.11 |
1.20 |
1.14 |
1.02 |
.80 |
.72 |
.89 |
| KLA/ATP | .08 |
.08 |
.12 |
.16 |
.23 |
.41 |
.64 |
|
Edg3 | |
NM_010101 |
endothelial differentiation, sphingolipid G-protein-coupled receptor, 3 (Edg3), mRNA [NM_010101] |
KLA | .97 |
.99 |
.96 |
.98 |
.96 |
.99 |
.95 |
| ATP | .98 |
1.04 |
1.09 |
1.08 |
1.06 |
1.02 |
1.05 |
| KLA/ATP | .92 |
.97 |
1.06 |
1.12 |
1.14 |
.98 |
1.07 |
|
Edg5 | |
L20334 |
gb|Mouse EDG-like receptor mRNA, partial cds. [L20334] |
KLA | 1.21 |
1.20 |
1.44 |
1.30 |
1.64 |
2.62 |
1.88 |
| ATP | .99 |
1.22 |
.88 |
.84 |
1.01 |
.99 |
1.42 |
| KLA/ATP | 1.23 |
1.29 |
.92 |
1.02 |
1.41 |
1.93 |
2.45 |
|
Edg5 | |
NM_010333 |
endothelial differentiation, sphingolipid G-protein-coupled receptor, 5 (Edg5), mRNA [NM_010333] |
KLA | 1.14 |
1.04 |
1.23 |
1.22 |
1.71 |
2.22 |
1.65 |
| ATP | 1.06 |
1.18 |
.80 |
.66 |
1.04 |
.86 |
1.44 |
| KLA/ATP | 1.16 |
1.21 |
.78 |
.97 |
1.46 |
1.78 |
2.74 |
|
Edg6 | |
NM_010102 |
endothelial differentiation, G-protein-coupled receptor 6 (Edg6), mRNA [NM_010102] |
KLA | 1.26 |
1.27 |
1.19 |
1.42 |
1.23 |
1.23 |
1.31 |
| ATP | 1.02 |
1.01 |
1.09 |
1.44 |
2.79 |
1.74 |
1.30 |
| KLA/ATP | 1.35 |
1.28 |
1.41 |
1.28 |
2.43 |
2.58 |
1.26 |
|
Edg8 | |
NM_053190 |
endothelial differentiation, sphingolipid G-protein-coupled receptor, 8 (Edg8), mRNA [NM_053190] |
KLA | 1.00 |
.98 |
1.01 |
.98 |
1.02 |
.99 |
1.17 |
| ATP | 1.02 |
1.01 |
.94 |
1.02 |
1.01 |
1.00 |
1.02 |
| KLA/ATP | 1.03 |
1.04 |
.96 |
.98 |
1.02 |
.97 |
.96 |
|
Edn1 | |
NM_010104 |
endothelin 1 (Edn1), mRNA [NM_010104] |
KLA | 73.36 |
71.33 |
61.92 |
68.69 |
46.94 |
32.60 |
13.54 |
| ATP | 1.23 |
1.89 |
4.18 |
10.86 |
17.85 |
11.03 |
1.91 |
| KLA/ATP | 67.27 |
76.78 |
116.70 |
90.29 |
76.38 |
29.71 |
8.04 |
|
Edn2 | |
NM_007902 |
endothelin 2 (Edn2), mRNA [NM_007902] |
KLA | 1.01 |
.97 |
1.01 |
1.04 |
1.03 |
1.03 |
1.09 |
| ATP | 1.03 |
1.06 |
.97 |
1.02 |
.98 |
.99 |
1.01 |
| KLA/ATP | 1.07 |
.99 |
.96 |
1.03 |
1.03 |
1.11 |
1.03 |
|
Edn3 | |
NM_007903 |
endothelin 3 (Edn3), mRNA [NM_007903] |
KLA | .98 |
1.00 |
.99 |
1.00 |
.99 |
1.00 |
1.03 |
| ATP | .99 |
.99 |
.99 |
1.03 |
1.00 |
1.04 |
1.01 |
| KLA/ATP | 1.02 |
.97 |
1.00 |
1.06 |
.99 |
1.04 |
.99 |
|
Ednra | |
AK042211 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630071G03 product:SIMILAR TO ENDOTHELIN RECEPTOR TYPE A, full insert sequence. [AK042211] |
KLA | 1.00 |
1.03 |
1.03 |
.97 |
.98 |
.99 |
.99 |
| ATP | .96 |
.97 |
1.05 |
.95 |
1.05 |
1.04 |
1.02 |
| KLA/ATP | .99 |
.98 |
1.00 |
1.05 |
.97 |
.98 |
.83 |
|
Ednra | |
NM_010332 |
endothelin receptor type A (Ednra), mRNA [NM_010332] |
KLA | 1.06 |
.99 |
1.02 |
.91 |
1.05 |
1.00 |
.99 |
| ATP | 1.01 |
.98 |
1.03 |
.98 |
.98 |
1.03 |
1.06 |
| KLA/ATP | 1.01 |
1.06 |
1.04 |
.93 |
.92 |
.92 |
.97 |
|
Ednrb | |
NM_007904 |
endothelin receptor type B (Ednrb), mRNA [NM_007904] |
KLA | 3.53 |
3.62 |
3.97 |
2.91 |
1.91 |
1.83 |
.88 |
| ATP | .97 |
.95 |
1.05 |
1.80 |
4.84 |
18.19 |
9.14 |
| KLA/ATP | 3.30 |
3.37 |
3.89 |
3.06 |
2.11 |
4.82 |
10.15 |
|
F2 | |
NM_010168 |
coagulation factor II (F2), mRNA [NM_010168] |
KLA | .99 |
.92 |
.95 |
1.01 |
1.01 |
1.06 |
.97 |
| ATP | 1.03 |
1.02 |
1.04 |
1.07 |
1.08 |
.96 |
.99 |
| KLA/ATP | .95 |
1.04 |
1.02 |
1.02 |
1.04 |
1.07 |
.99 |
|
F2r | |
NM_010169 |
coagulation factor II (thrombin) receptor (F2r), mRNA [NM_010169] |
KLA | 3.73 |
3.81 |
3.68 |
3.00 |
2.75 |
1.49 |
1.01 |
| ATP | .98 |
1.02 |
1.25 |
1.24 |
1.31 |
1.63 |
1.16 |
| KLA/ATP | 3.51 |
4.05 |
3.49 |
3.00 |
2.48 |
1.69 |
1.23 |
|
F2rl1 | |
NM_007974 |
coagulation factor II (thrombin) receptor-like 1 (F2rl1), mRNA [NM_007974] |
KLA | 1.03 |
1.05 |
1.00 |
.98 |
1.01 |
1.03 |
1.04 |
| ATP | 1.00 |
.99 |
1.03 |
1.09 |
1.03 |
1.04 |
1.09 |
| KLA/ATP | 1.07 |
1.02 |
.95 |
1.10 |
1.02 |
1.02 |
1.02 |
|
F2rl2 | |
NM_010170 |
coagulation factor II (thrombin) receptor-like 2 (F2rl2), mRNA [NM_010170] |
KLA | 1.04 |
1.02 |
.99 |
1.00 |
1.07 |
1.02 |
.96 |
| ATP | .98 |
1.01 |
1.00 |
.92 |
1.00 |
.98 |
.98 |
| KLA/ATP | 1.04 |
1.00 |
.95 |
.94 |
1.04 |
.99 |
.94 |
|
F2rl3 | |
NM_007975 |
coagulation factor II (thrombin) receptor-like 3 (F2rl3), mRNA [NM_007975] |
KLA | 1.02 |
.92 |
1.01 |
.98 |
.91 |
.97 |
.96 |
| ATP | .99 |
.95 |
.99 |
.95 |
1.00 |
.98 |
1.01 |
| KLA/ATP | 1.03 |
.99 |
1.04 |
.94 |
.95 |
.98 |
.87 |
|
Fpr1 | |
NM_013521 |
formyl peptide receptor 1 (Fpr1), mRNA [NM_013521] |
KLA | 12.54 |
11.98 |
13.69 |
17.91 |
17.62 |
21.59 |
20.02 |
| ATP | 1.09 |
1.02 |
1.66 |
1.90 |
2.46 |
10.47 |
6.95 |
| KLA/ATP | 10.93 |
13.61 |
16.67 |
13.71 |
13.37 |
13.41 |
21.96 |
|
Fpr2 | |
NM_008039 |
formyl peptide receptor 2 (Fpr2), mRNA [NM_008039] |
KLA | 30.10 |
32.49 |
33.82 |
36.00 |
37.31 |
42.10 |
32.37 |
| ATP | 1.10 |
1.05 |
1.45 |
1.72 |
2.69 |
13.48 |
7.36 |
| KLA/ATP | 27.60 |
31.79 |
38.83 |
33.94 |
35.28 |
33.33 |
38.38 |
|
Fshb | |
NM_008045 |
follicle stimulating hormone beta (Fshb), mRNA [NM_008045] |
KLA | 1.05 |
1.05 |
1.01 |
.98 |
1.05 |
1.03 |
1.07 |
| ATP | 1.02 |
1.01 |
1.02 |
.94 |
1.02 |
1.02 |
.96 |
| KLA/ATP | 1.10 |
1.03 |
.99 |
1.00 |
1.07 |
1.06 |
.98 |
|
Fshr | |
NM_013523 |
follicle stimulating hormone receptor (Fshr), mRNA [NM_013523] |
KLA | .98 |
1.03 |
.89 |
.95 |
.99 |
1.01 |
.98 |
| ATP | 1.01 |
1.03 |
1.02 |
.96 |
.95 |
.97 |
1.04 |
| KLA/ATP | .93 |
.94 |
1.06 |
.97 |
.92 |
.93 |
1.03 |
|
Gabbr1 | |
NM_019439 |
gamma-aminobutyric acid (GABA-B) receptor, 1 (Gabbr1), mRNA [NM_019439] |
KLA | 1.00 |
1.03 |
1.04 |
1.01 |
.97 |
1.01 |
.99 |
| ATP | .98 |
.96 |
1.03 |
1.01 |
.96 |
1.03 |
.99 |
| KLA/ATP | .97 |
1.00 |
.97 |
1.02 |
1.02 |
.97 |
1.01 |
|
Gabbr2 | |
NM_001081141 |
gamma-aminobutyric acid (GABA) B receptor 2 (Gabbr2), mRNA [NM_001081141] |
KLA | 1.06 |
.98 |
.99 |
1.03 |
1.09 |
1.06 |
1.02 |
| ATP | 1.03 |
1.06 |
1.05 |
1.14 |
1.10 |
1.00 |
1.04 |
| KLA/ATP | 1.09 |
1.10 |
1.12 |
1.11 |
1.06 |
1.04 |
1.06 |
|
Gabra1 | |
NM_010250 |
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 1 (Gabra1), mRNA [NM_010250] |
KLA | 1.01 |
.99 |
1.01 |
1.06 |
1.00 |
1.07 |
1.04 |
| ATP | 1.03 |
1.04 |
1.07 |
1.05 |
1.02 |
.99 |
.99 |
| KLA/ATP | 1.05 |
1.02 |
1.04 |
1.06 |
1.05 |
1.06 |
1.01 |
|
Gabra2 | |
AK048165 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130038H23 product:gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 2, full insert sequence [AK048165] |
KLA | .98 |
1.06 |
1.03 |
1.01 |
1.03 |
1.03 |
.98 |
| ATP | 1.00 |
1.00 |
1.05 |
1.07 |
.96 |
.92 |
1.04 |
| KLA/ATP | 1.02 |
1.09 |
.97 |
1.02 |
.99 |
.98 |
.80 |
|
Gabra2 | |
NM_008066 |
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 2 (Gabra2), mRNA [NM_008066] |
KLA | .99 |
1.01 |
1.10 |
1.05 |
.96 |
.93 |
.98 |
| ATP | 1.09 |
.99 |
.99 |
.98 |
.97 |
.93 |
.94 |
| KLA/ATP | .99 |
.97 |
.97 |
.96 |
1.02 |
.97 |
1.04 |
|
Gabra3 | |
NM_008067 |
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 3 (Gabra3), mRNA [NM_008067] |
KLA | 1.00 |
1.01 |
1.03 |
.99 |
1.01 |
1.00 |
1.01 |
| ATP | 1.03 |
.97 |
1.03 |
.98 |
.98 |
.97 |
1.00 |
| KLA/ATP | .99 |
1.08 |
1.05 |
.98 |
1.00 |
1.03 |
.96 |
|
Gabra4 | |
NM_010251 |
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 4 (Gabra4), mRNA [NM_010251] |
KLA | .98 |
1.01 |
1.02 |
.99 |
1.03 |
.95 |
1.02 |
| ATP | .98 |
.94 |
1.03 |
1.09 |
1.00 |
1.06 |
1.03 |
| KLA/ATP | 1.04 |
1.00 |
1.02 |
.97 |
1.02 |
1.05 |
.98 |
|
Gabra5 | |
NM_176942 |
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 5 (Gabra5), mRNA [NM_176942] |
KLA | .97 |
.92 |
1.00 |
.97 |
1.01 |
.99 |
.97 |
| ATP | 1.02 |
.99 |
1.03 |
.98 |
1.00 |
.98 |
1.00 |
| KLA/ATP | .97 |
.99 |
1.01 |
1.00 |
.97 |
.97 |
.92 |
|
Gabra6 | |
NM_008068 |
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 6 (Gabra6), transcript variant 2, mRNA [NM_008068] |
KLA | 1.05 |
1.02 |
.96 |
1.06 |
.96 |
1.02 |
1.07 |
| ATP | 1.01 |
.96 |
1.03 |
1.00 |
.99 |
.94 |
1.07 |
| KLA/ATP | .99 |
.99 |
1.09 |
1.01 |
1.13 |
.97 |
1.07 |
|
Gabrb1 | |
NM_008069 |
gamma-aminobutyric acid (GABA-A) receptor, subunit beta 1 (Gabrb1), mRNA [NM_008069] |
KLA | .99 |
.98 |
.99 |
1.00 |
1.02 |
.99 |
.95 |
| ATP | 1.00 |
1.04 |
.98 |
1.01 |
1.05 |
1.02 |
1.03 |
| KLA/ATP | 1.00 |
.96 |
1.00 |
.96 |
1.05 |
1.03 |
1.04 |
|
Gabrb2 | |
NM_008070 |
gamma-aminobutyric acid (GABA-A) receptor, subunit beta 2 (Gabrb2), mRNA [NM_008070] |
KLA | 1.04 |
1.04 |
1.03 |
1.04 |
1.00 |
.98 |
1.03 |
| ATP | .99 |
1.01 |
1.00 |
1.01 |
1.03 |
.99 |
.93 |
| KLA/ATP | 1.05 |
1.06 |
1.05 |
.96 |
.97 |
.94 |
1.00 |
|
Gabrb3 | |
NM_008071 |
gamma-aminobutyric acid (GABA-A) receptor, subunit beta 3 (Gabrb3), transcript variant 1, mRNA [NM_008071] |
KLA | .99 |
.99 |
.99 |
1.01 |
.99 |
.97 |
1.00 |
| ATP | .98 |
1.02 |
1.00 |
.99 |
.99 |
.99 |
1.00 |
| KLA/ATP | 1.00 |
1.03 |
1.05 |
.97 |
.98 |
.99 |
.99 |
|
Gabrd | |
NM_008072 |
gamma-aminobutyric acid (GABA-A) receptor, subunit delta (Gabrd), mRNA [NM_008072] |
KLA | 1.36 |
1.25 |
1.30 |
1.25 |
1.16 |
1.42 |
1.07 |
| ATP | .97 |
.82 |
.91 |
.80 |
.74 |
1.02 |
.96 |
| KLA/ATP | 1.12 |
1.10 |
1.06 |
.87 |
.89 |
1.04 |
1.12 |
|
Gabre | |
NM_017369 |
gamma-aminobutyric acid (GABA-A) receptor, subunit epsilon (Gabre), mRNA [NM_017369] |
KLA | .97 |
1.04 |
.98 |
1.01 |
1.03 |
.99 |
1.05 |
| ATP | .96 |
1.00 |
.96 |
1.04 |
.98 |
.99 |
1.02 |
| KLA/ATP | 1.00 |
1.02 |
1.01 |
.97 |
.93 |
.93 |
.89 |
|
Gabrg1 | |
AK038686 |
adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230055A07 product:gamma-aminobutyric acid (GABA-A) receptor, subunit gamma 1, full insert sequence. [AK038686] |
KLA | .98 |
1.06 |
1.09 |
1.00 |
1.01 |
1.05 |
1.07 |
| ATP | .96 |
.99 |
1.03 |
1.03 |
1.03 |
1.00 |
1.08 |
| KLA/ATP | 1.04 |
1.04 |
.90 |
1.04 |
1.04 |
1.08 |
1.07 |
|
Gabrg1 | |
NM_010252 |
gamma-aminobutyric acid (GABA-A) receptor, subunit gamma 1 (Gabrg1), mRNA [NM_010252] |
KLA | 1.00 |
1.00 |
.98 |
.99 |
1.01 |
1.01 |
1.01 |
| ATP | 1.00 |
.99 |
1.00 |
1.03 |
1.01 |
1.02 |
1.01 |
| KLA/ATP | .98 |
.98 |
1.00 |
1.00 |
1.00 |
1.00 |
1.02 |
|
Gabrg2 | |
NM_008073 |
gamma-aminobutyric acid (GABA-A) receptor, subunit gamma 2 (Gabrg2), transcript variant 1, mRNA [NM_008073] |
KLA | 1.04 |
1.03 |
1.03 |
.97 |
.99 |
.98 |
1.03 |
| ATP | .97 |
1.00 |
1.05 |
1.00 |
1.01 |
1.01 |
1.01 |
| KLA/ATP | 1.01 |
.94 |
1.04 |
1.06 |
1.01 |
.95 |
1.02 |
|
Gabrg3 | |
NM_008074 |
gamma-aminobutyric acid (GABA-A) receptor, subunit gamma 3 (Gabrg3), mRNA [NM_008074] |
KLA | .98 |
1.03 |
1.01 |
1.05 |
1.01 |
1.08 |
1.09 |
| ATP | 1.04 |
1.09 |
1.02 |
1.06 |
1.07 |
1.05 |
1.06 |
| KLA/ATP | 1.01 |
1.14 |
1.07 |
1.04 |
1.04 |
1.15 |
1.01 |
|
Gabrp | |
NM_146017 |
gamma-aminobutyric acid (GABA-A) receptor, pi (Gabrp), mRNA [NM_146017] |
KLA | 1.03 |
.97 |
.99 |
1.08 |
.98 |
1.08 |
1.00 |
| ATP | .95 |
1.04 |
1.03 |
.95 |
.95 |
.95 |
1.05 |
| KLA/ATP | .97 |
.98 |
.98 |
.98 |
.95 |
.94 |
.86 |
|
Gabrq | |
NM_020488 |
gamma-aminobutyric acid (GABA-A) receptor, subunit theta (Gabrq), mRNA [NM_020488] |
KLA | 1.00 |
.97 |
1.04 |
1.02 |
1.02 |
.88 |
.96 |
| ATP | 1.03 |
1.03 |
.99 |
.94 |
1.05 |
.94 |
.90 |
| KLA/ATP | .94 |
1.00 |
1.03 |
.93 |
.98 |
1.01 |
1.01 |
|
Gabrr1 | |
NM_008075 |
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 1 (Gabrr1), mRNA [NM_008075] |
KLA | 1.37 |
1.28 |
1.42 |
1.45 |
1.28 |
1.19 |
1.01 |
| ATP | .99 |
1.01 |
1.30 |
1.10 |
1.13 |
1.05 |
.80 |
| KLA/ATP | 1.25 |
1.36 |
1.40 |
1.29 |
1.16 |
1.00 |
.79 |
|
Gabrr2 | |
NM_008076 |
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 2 (Gabrr2), mRNA [NM_008076] |
KLA | 1.03 |
1.04 |
.99 |
1.02 |
1.05 |
.98 |
1.12 |
| ATP | 1.07 |
.98 |
1.00 |
1.08 |
1.04 |
.97 |
1.02 |
| KLA/ATP | 1.04 |
1.00 |
.94 |
.99 |
1.05 |
1.05 |
1.05 |
|
Gal | |
NM_010253 |
galanin (Gal), mRNA [NM_010253] |
KLA | .98 |
1.00 |
1.09 |
1.08 |
1.09 |
.98 |
1.09 |
| ATP | 1.07 |
1.06 |
1.16 |
1.77 |
1.93 |
1.74 |
1.57 |
| KLA/ATP | 1.20 |
1.08 |
1.23 |
1.43 |
1.54 |
1.45 |
1.38 |
|
Galr1 | |
NM_008082 |
galanin receptor 1 (Galr1), mRNA [NM_008082] |
KLA | .98 |
1.01 |
1.08 |
1.07 |
1.02 |
1.00 |
.95 |
| ATP | 1.02 |
1.00 |
.94 |
.98 |
.98 |
1.00 |
.94 |
| KLA/ATP | .95 |
1.11 |
.96 |
1.01 |
1.00 |
.95 |
1.00 |
|
Galr2 | |
NM_010254 |
galanin receptor 2 (Galr2), mRNA [NM_010254] |
KLA | 1.00 |
1.04 |
1.08 |
.96 |
1.02 |
1.04 |
1.03 |
| ATP | 1.06 |
1.12 |
1.10 |
1.08 |
1.05 |
1.03 |
1.02 |
| KLA/ATP | 1.01 |
1.05 |
1.06 |
1.00 |
.98 |
1.00 |
1.02 |
|
Galr3 | |
NM_015738 |
galanin receptor 3 (Galr3), mRNA [NM_015738] |
KLA | 1.22 |
1.17 |
1.32 |
1.30 |
1.34 |
1.45 |
1.18 |
| ATP | 1.03 |
1.00 |
1.28 |
1.39 |
1.38 |
1.36 |
1.21 |
| KLA/ATP | 1.27 |
1.39 |
1.61 |
1.67 |
1.57 |
1.57 |
1.44 |
|
Gcg | |
AK050538 |
adult pancreas islet cells cDNA, RIKEN full-length enriched library, clone:C820012C23 product:unclassifiable, full insert sequence [AK050538] |
KLA | 1.02 |
1.03 |
1.02 |
1.04 |
1.01 |
.95 |
.98 |
| ATP | .95 |
.95 |
1.02 |
.98 |
.93 |
1.06 |
1.02 |
| KLA/ATP | 1.02 |
1.02 |
1.07 |
1.24 |
1.07 |
1.05 |
1.02 |
|
Gcg | |
NM_008100 |
glucagon (Gcg), mRNA [NM_008100] |
KLA | 1.15 |
1.16 |
1.18 |
1.14 |
1.12 |
1.11 |
1.07 |
| ATP | 1.00 |
1.01 |
1.05 |
1.06 |
1.34 |
1.43 |
1.08 |
| KLA/ATP | 1.15 |
1.16 |
1.27 |
7.81 |
6.64 |
5.01 |
1.81 |
|
Gcgr | |
L38613 |
glucagon receptor mRNA, complete cds. [L38613] |
KLA | .95 |
1.03 |
1.02 |
1.03 |
1.01 |
1.00 |
1.04 |
| ATP | .93 |
1.02 |
1.00 |
.96 |
1.09 |
.90 |
.95 |
| KLA/ATP | .98 |
1.09 |
1.01 |
1.01 |
.99 |
1.04 |
.96 |
|
Gh | |
NM_008117 |
growth hormone (Gh), mRNA [NM_008117] |
KLA | 1.02 |
1.03 |
1.01 |
.98 |
.98 |
.94 |
.98 |
| ATP | .94 |
1.02 |
1.06 |
1.20 |
.99 |
.95 |
.96 |
| KLA/ATP | .97 |
1.03 |
1.03 |
1.09 |
.96 |
1.00 |
1.05 |
|
Ghr | |
AK053579 |
0 day neonate eyeball cDNA, RIKEN full-length enriched library, clone:E130111P21 product:growth hormone receptor, full insert sequence. [AK053579] |
KLA | 1.10 |
1.07 |
1.09 |
1.01 |
1.03 |
.96 |
1.02 |
| ATP | 1.04 |
1.01 |
1.06 |
.96 |
1.03 |
.96 |
1.02 |
| KLA/ATP | 1.08 |
1.15 |
1.15 |
1.04 |
1.02 |
1.07 |
1.03 |
|
Ghr | |
NM_010284 |
growth hormone receptor (Ghr), transcript variant 1, mRNA [NM_010284] |
KLA | 1.09 |
1.10 |
1.29 |
1.31 |
1.23 |
1.09 |
.97 |
| ATP | 1.00 |
1.02 |
1.03 |
1.02 |
.93 |
.96 |
.97 |
| KLA/ATP | 1.17 |
1.20 |
1.15 |
1.15 |
1.07 |
.96 |
.96 |
|
Ghrh | |
NM_010285 |
growth hormone releasing hormone (Ghrh), mRNA [NM_010285] |
KLA | 1.02 |
1.08 |
1.04 |
1.08 |
1.09 |
1.03 |
.96 |
| ATP | .98 |
.97 |
.98 |
.97 |
1.01 |
1.04 |
.92 |
| KLA/ATP | 1.01 |
1.07 |
1.10 |
.99 |
1.04 |
.94 |
.98 |
|
Ghrhr | |
NM_001003685 |
growth hormone releasing hormone receptor (Ghrhr), mRNA [NM_001003685] |
KLA | 1.05 |
.98 |
1.02 |
.97 |
1.02 |
.92 |
1.01 |
| ATP | 1.07 |
.97 |
1.05 |
.98 |
1.03 |
.95 |
1.02 |
| KLA/ATP | 1.06 |
1.10 |
1.02 |
1.03 |
1.02 |
.99 |
.91 |
|
Ghrl | |
NM_021488 |
ghrelin (Ghrl), mRNA [NM_021488] |
KLA | 1.07 |
1.08 |
1.05 |
1.08 |
1.12 |
1.09 |
1.01 |
| ATP | .97 |
1.02 |
1.19 |
1.22 |
1.19 |
1.20 |
.97 |
| KLA/ATP | 1.02 |
1.01 |
1.09 |
1.21 |
1.21 |
1.29 |
1.13 |
|
Ghsr | |
NM_177330 |
growth hormone secretagogue receptor (Ghsr), mRNA [NM_177330] |
KLA | 1.02 |
.95 |
1.04 |
1.05 |
1.00 |
1.07 |
1.03 |
| ATP | .99 |
1.01 |
1.01 |
.98 |
1.08 |
.99 |
1.03 |
| KLA/ATP | 1.01 |
1.07 |
1.03 |
1.03 |
1.04 |
1.03 |
1.05 |
|
Gip | |
NM_008119 |
gastric inhibitory polypeptide (Gip), mRNA [NM_008119] |
KLA | 1.07 |
1.03 |
.94 |
1.06 |
1.10 |
1.03 |
1.05 |
| ATP | 1.05 |
1.00 |
.96 |
1.00 |
.96 |
.97 |
.97 |
| KLA/ATP | .92 |
.95 |
1.04 |
1.00 |
.95 |
1.03 |
1.02 |
|
Gipr | |
NM_001080815 |
gastric inhibitory polypeptide receptor (Gipr), mRNA [NM_001080815] |
KLA | 1.09 |
1.06 |
1.06 |
1.04 |
1.08 |
1.06 |
1.10 |
| ATP | 1.02 |
1.03 |
.96 |
.96 |
1.05 |
1.04 |
1.16 |
| KLA/ATP | 1.04 |
1.03 |
1.07 |
1.00 |
.97 |
1.01 |
1.30 |
|
Glp1r | |
NM_021332 |
glucagon-like peptide 1 receptor (Glp1r), mRNA [NM_021332] |
KLA | .99 |
.97 |
.98 |
.95 |
1.03 |
.99 |
.99 |
| ATP | .99 |
.99 |
.97 |
1.01 |
.97 |
.99 |
1.02 |
| KLA/ATP | .97 |
1.03 |
1.02 |
1.00 |
.98 |
.98 |
1.01 |
|
Glp2r | |
NM_175681 |
glucagon-like peptide 2 receptor (Glp2r), mRNA [NM_175681] |
KLA | 1.03 |
1.01 |
1.04 |
1.07 |
1.02 |
.97 |
1.02 |
| ATP | 1.02 |
.96 |
1.04 |
1.06 |
1.03 |
1.02 |
1.02 |
| KLA/ATP | 1.05 |
1.07 |
1.11 |
1.03 |
1.01 |
1.05 |
1.06 |
|
Glra1 | |
NM_020492 |
glycine receptor, alpha 1 subunit (Glra1), mRNA [NM_020492] |
KLA | 1.01 |
1.01 |
1.01 |
1.01 |
1.02 |
1.05 |
.97 |
| ATP | .99 |
.97 |
1.24 |
1.28 |
1.04 |
1.01 |
1.04 |
| KLA/ATP | 1.01 |
1.06 |
1.06 |
1.18 |
1.07 |
1.01 |
1.05 |
|
Glra2 | |
NM_183427 |
glycine receptor, alpha 2 subunit (Glra2), mRNA [NM_183427] |
KLA | .98 |
.97 |
.99 |
1.00 |
1.02 |
1.05 |
1.01 |
| ATP | .98 |
.93 |
1.04 |
.97 |
.97 |
1.07 |
1.05 |
| KLA/ATP | .98 |
.97 |
1.06 |
1.02 |
.97 |
.99 |
1.04 |
|
Glra3 | |
AK038618 |
adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230050P16 product:glycine receptor, alpha 3 subunit, full insert sequence [AK038618] |
KLA | .94 |
.95 |
.96 |
1.03 |
1.00 |
1.03 |
1.03 |
| ATP | 1.06 |
1.02 |
1.06 |
1.06 |
.98 |
1.04 |
1.03 |
| KLA/ATP | 1.03 |
.93 |
.87 |
.97 |
1.08 |
1.06 |
1.02 |
|
Glra3 | |
NM_080438 |
glycine receptor, alpha 3 subunit (Glra3), mRNA [NM_080438] |
KLA | 1.00 |
1.02 |
1.03 |
.97 |
.97 |
1.04 |
.99 |
| ATP | .99 |
.93 |
.96 |
1.06 |
.96 |
1.05 |
1.02 |
| KLA/ATP | .99 |
1.03 |
.95 |
.97 |
1.05 |
1.07 |
1.04 |
|
Glrb | |
NM_010298 |
glycine receptor, beta subunit (Glrb), mRNA [NM_010298] |
KLA | 1.05 |
1.00 |
1.10 |
.98 |
.99 |
1.03 |
.94 |
| ATP | .93 |
1.02 |
1.06 |
1.02 |
.96 |
1.04 |
1.04 |
| KLA/ATP | 1.06 |
.96 |
.96 |
.99 |
.94 |
.96 |
1.02 |
|
Gnrh1 | |
NM_008145 |
gonadotropin releasing hormone 1 (Gnrh1), mRNA [NM_008145] |
KLA | .80 |
.84 |
.94 |
.97 |
.93 |
1.04 |
.97 |
| ATP | 1.01 |
1.10 |
1.21 |
1.12 |
3.15 |
1.61 |
.95 |
| KLA/ATP | .84 |
.92 |
1.03 |
.93 |
2.48 |
1.56 |
1.23 |
|
Gnrhr | |
NM_010323 |
gonadotropin releasing hormone receptor (Gnrhr), mRNA [NM_010323] |
KLA | 1.01 |
.98 |
1.04 |
1.00 |
1.01 |
.96 |
.99 |
| ATP | 1.03 |
1.00 |
.98 |
1.06 |
1.01 |
1.00 |
.99 |
| KLA/ATP | 1.05 |
1.04 |
1.00 |
.97 |
1.00 |
.98 |
1.08 |
|
Gpr156 | |
NM_153394 |
G protein-coupled receptor 156 (Gpr156), mRNA [NM_153394] |
KLA | .99 |
1.03 |
.99 |
.99 |
1.05 |
1.03 |
.99 |
| ATP | .99 |
1.02 |
1.03 |
1.00 |
.96 |
1.02 |
1.05 |
| KLA/ATP | 1.01 |
1.00 |
1.02 |
1.00 |
1.00 |
1.05 |
.98 |
|
Gpr35 | |
NM_022320 |
G protein-coupled receptor 35 (Gpr35), transcript variant 1, mRNA [NM_022320] |
KLA | 1.08 |
1.10 |
1.09 |
1.49 |
2.77 |
2.80 |
1.59 |
| ATP | 1.02 |
1.07 |
1.15 |
1.20 |
1.17 |
2.25 |
2.87 |
| KLA/ATP | 1.05 |
1.04 |
1.16 |
1.31 |
1.45 |
3.76 |
6.97 |
|
Gpr50 | |
NM_010340 |
G-protein-coupled receptor 50 (Gpr50), mRNA [NM_010340] |
KLA | .78 |
.82 |
.79 |
.88 |
.85 |
.88 |
1.02 |
| ATP | .98 |
1.08 |
.90 |
.97 |
.89 |
.81 |
.89 |
| KLA/ATP | .84 |
.82 |
.86 |
.93 |
.79 |
.75 |
.90 |
|
Gpr77 | |
NM_176912 |
G protein-coupled receptor 77 (Gpr77), mRNA [NM_176912] |
KLA | .33 |
.32 |
.26 |
.29 |
.29 |
.45 |
.57 |
| ATP | .94 |
.97 |
1.22 |
.92 |
.37 |
.35 |
.76 |
| KLA/ATP | .33 |
.38 |
.45 |
.37 |
.35 |
.23 |
.67 |
|
Gpr83 | |
AK041527 |
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630019F13 product:PROBABLE G PROTEIN-COUPLED RECEPTOR GPR72 PRECURSOR (GLUCOCORTICOID- INDUCED RECEPTOR), full insert sequence [AK041527] |
KLA | 1.00 |
1.05 |
1.02 |
1.05 |
1.01 |
1.01 |
1.00 |
| ATP | 1.02 |
1.04 |
.95 |
1.05 |
1.00 |
1.04 |
1.03 |
| KLA/ATP | .97 |
1.01 |
1.00 |
1.02 |
1.00 |
1.09 |
1.01 |
|
Gpr83 | |
NM_010287 |
G protein-coupled receptor 83 (Gpr83), mRNA [NM_010287] |
KLA | 1.01 |
.97 |
1.02 |
1.03 |
1.00 |
1.05 |
1.05 |
| ATP | .92 |
1.09 |
.97 |
1.03 |
1.26 |
1.50 |
1.10 |
| KLA/ATP | 1.01 |
1.04 |
1.11 |
1.05 |
1.21 |
1.59 |
1.12 |
|
Gria1 | |
NM_008165 |
glutamate receptor, ionotropic, AMPA1 (alpha 1) (Gria1), transcript variant 2, mRNA [NM_008165] |
KLA | .97 |
1.02 |
1.02 |
1.01 |
1.03 |
1.02 |
1.11 |
| ATP | 1.03 |
.97 |
1.05 |
1.03 |
1.01 |
1.01 |
1.01 |
| KLA/ATP | 1.02 |
.99 |
1.01 |
1.06 |
1.15 |
1.06 |
1.05 |
|
Gria2 | |
BC048248 |
glutamate receptor, ionotropic, AMPA2 (alpha 2), mRNA (cDNA clone MGC:54603 IMAGE:6494013), complete cds. [BC048248] |
KLA | 1.00 |
1.01 |
1.05 |
1.00 |
1.03 |
.97 |
1.06 |
| ATP | .98 |
1.00 |
1.00 |
.96 |
1.03 |
1.05 |
1.04 |
| KLA/ATP | .98 |
1.08 |
.99 |
1.04 |
1.06 |
1.02 |
1.05 |
|
Gria2 | |
NM_013540 |
glutamate receptor, ionotropic, AMPA2 (alpha 2) (Gria2), transcript variant 2, mRNA [NM_013540] |
KLA | 1.02 |
1.02 |
.98 |
1.01 |
.98 |
1.02 |
1.01 |
| ATP | .95 |
1.01 |
.95 |
.99 |
1.09 |
1.02 |
1.09 |
| KLA/ATP | 1.06 |
.92 |
.96 |
.99 |
1.00 |
1.03 |
1.00 |
|
Gria3 | |
AK161163 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4831401I16 product:glutamate receptor, ionotropic, AMPA3 (alpha 3), full insert sequence. [AK161163] |
KLA | 1.01 |
.96 |
.97 |
.95 |
.99 |
.84 |
.81 |
| ATP | 1.05 |
1.04 |
1.07 |
.86 |
.88 |
.84 |
.65 |
| KLA/ATP | .94 |
.95 |
1.06 |
.83 |
.79 |
.75 |
.66 |
|
Gria3 | |
NM_016886 |
glutamate receptor, ionotropic, AMPA3 (alpha 3) (Gria3), mRNA [NM_016886] |
KLA | 1.04 |
.95 |
1.05 |
.98 |
.98 |
.97 |
.95 |
| ATP | 1.00 |
1.08 |
1.01 |
.97 |
.93 |
.98 |
.97 |
| KLA/ATP | 1.03 |
.93 |
.93 |
.98 |
.96 |
1.03 |
.89 |
|
Gria4 | |
NM_019691 |
glutamate receptor, ionotropic, AMPA4 (alpha 4) (Gria4), transcript variant 1, mRNA [NM_019691] |
KLA | 1.05 |
1.05 |
1.00 |
.97 |
1.00 |
1.04 |
1.01 |
| ATP | 1.01 |
1.03 |
1.24 |
.99 |
.95 |
.99 |
1.02 |
| KLA/ATP | .99 |
1.03 |
1.04 |
1.00 |
.98 |
.97 |
1.02 |
|
Grid1 | |
NM_008166 |
glutamate receptor, ionotropic, delta 1 (Grid1), mRNA [NM_008166] |
KLA | 1.06 |
.99 |
1.07 |
1.00 |
.97 |
1.00 |
1.01 |
| ATP | 1.08 |
1.05 |
1.05 |
.97 |
.95 |
1.00 |
1.04 |
| KLA/ATP | 1.03 |
.95 |
1.13 |
1.00 |
1.06 |
1.00 |
.97 |
|
Grid2 | |
AK032669 |
10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:6530411F08 product:glutamate receptor, ionotropic, delta 2, full insert sequence. [AK032669] |
KLA | 1.00 |
1.02 |
1.01 |
1.01 |
1.01 |
1.01 |
1.00 |
| ATP | 1.01 |
1.01 |
.99 |
.99 |
1.01 |
1.01 |
1.00 |
| KLA/ATP | 1.02 |
1.01 |
1.01 |
1.02 |
.99 |
1.01 |
.99 |
|
Grid2 | |
AK036230 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630046P05 product:glutamate receptor, ionotropic, delta 2, full insert sequence. [AK036230] |
KLA | 1.01 |
.97 |
1.01 |
.96 |
.96 |
.96 |
1.06 |
| ATP | 1.00 |
1.01 |
1.01 |
.97 |
1.00 |
.97 |
1.03 |
| KLA/ATP | 1.02 |
1.06 |
1.02 |
.92 |
.95 |
.95 |
.99 |
|
Grik1 | |
NM_010348 |
glutamate receptor, ionotropic, kainate 1 (Grik1), transcript variant 2, mRNA [NM_010348] |
KLA | 1.04 |
1.05 |
.99 |
1.03 |
.99 |
1.04 |
.89 |
| ATP | .98 |
1.06 |
1.02 |
.94 |
.94 |
1.01 |
1.08 |
| KLA/ATP | 1.07 |
.95 |
1.00 |
.97 |
1.05 |
.97 |
1.03 |
|
Grik1 | |
NM_146072 |
glutamate receptor, ionotropic, kainate 1 (Grik1), transcript variant 1, mRNA [NM_146072] |
KLA | 1.00 |
.98 |
.99 |
1.04 |
.98 |
.96 |
.94 |
| ATP | .97 |
.96 |
1.03 |
1.02 |
.94 |
.94 |
.97 |
| KLA/ATP | .93 |
1.02 |
1.01 |
1.02 |
1.01 |
.97 |
1.02 |
|
Grik2 | |
NM_010349 |
glutamate receptor, ionotropic, kainate 2 (beta 2) (Grik2), transcript variant 2, mRNA [NM_010349] |
KLA | 1.04 |
.99 |
.97 |
1.02 |
1.02 |
.99 |
.98 |
| ATP | 1.02 |
1.02 |
.99 |
.99 |
1.01 |
.98 |
.96 |
| KLA/ATP | .98 |
1.01 |
1.03 |
1.00 |
.96 |
.98 |
1.03 |
|
Grik3 | |
NM_001081097 |
glutamate receptor, ionotropic, kainate 3 (Grik3), mRNA [NM_001081097] |
KLA | .97 |
.98 |
1.00 |
1.07 |
1.08 |
1.05 |
.98 |
| ATP | 1.00 |
.98 |
.98 |
.99 |
.98 |
1.03 |
1.02 |
| KLA/ATP | 1.01 |
.98 |
1.06 |
1.07 |
.97 |
1.04 |
1.03 |
|
Grik4 | |
NM_175481 |
glutamate receptor, ionotropic, kainate 4 (Grik4), mRNA [NM_175481] |
KLA | 1.00 |
1.01 |
1.01 |
1.11 |
1.00 |
.95 |
1.03 |
| ATP | 1.05 |
1.02 |
1.00 |
1.00 |
1.12 |
.91 |
1.06 |
| KLA/ATP | .96 |
1.01 |
1.04 |
.99 |
.98 |
1.00 |
1.05 |
|
Grik5 | |
NM_008168 |
glutamate receptor, ionotropic, kainate 5 (gamma 2) (Grik5), mRNA [NM_008168] |
KLA | .88 |
.88 |
.91 |
.89 |
.86 |
.87 |
.87 |
| ATP | 1.01 |
1.03 |
.97 |
1.06 |
.83 |
.73 |
.83 |
| KLA/ATP | .91 |
.87 |
.95 |
.92 |
.80 |
.77 |
.92 |
|
Grin1 | |
NM_008169 |
glutamate receptor, ionotropic, NMDA1 (zeta 1) (Grin1), mRNA [NM_008169] |
KLA | .90 |
.97 |
.91 |
.98 |
.93 |
.94 |
1.01 |
| ATP | 1.04 |
1.04 |
1.02 |
1.08 |
.96 |
.91 |
.93 |
| KLA/ATP | .90 |
.99 |
.95 |
.95 |
.94 |
.88 |
.89 |
|
Grin2a | |
NM_008170 |
glutamate receptor, ionotropic, NMDA2A (epsilon 1) (Grin2a), mRNA [NM_008170] |
KLA | 1.00 |
1.08 |
1.00 |
1.03 |
1.09 |
1.02 |
1.04 |
| ATP | .96 |
.94 |
1.00 |
.98 |
1.03 |
.97 |
1.01 |
| KLA/ATP | .95 |
1.02 |
1.03 |
.95 |
.99 |
.99 |
.95 |
|
Grin2b | |
NM_008171 |
glutamate receptor, ionotropic, NMDA2B (epsilon 2) (Grin2b), mRNA [NM_008171] |
KLA | 1.03 |
1.02 |
1.10 |
1.09 |
1.02 |
1.03 |
1.08 |
| ATP | 1.15 |
1.07 |
1.05 |
1.07 |
1.08 |
1.04 |
1.02 |
| KLA/ATP | 1.10 |
1.04 |
1.07 |
1.13 |
1.09 |
1.08 |
1.06 |
|
Grin2c | |
NM_010350 |
glutamate receptor, ionotropic, NMDA2C (epsilon 3) (Grin2c), mRNA [NM_010350] |
KLA | 1.09 |
1.13 |
1.19 |
1.24 |
1.14 |
1.15 |
1.09 |
| ATP | 1.05 |
.96 |
.98 |
.98 |
.94 |
1.01 |
1.10 |
| KLA/ATP | 1.08 |
1.14 |
1.09 |
1.05 |
1.05 |
.98 |
1.01 |
|
Grin2d | |
NM_008172 |
glutamate receptor, ionotropic, NMDA2D (epsilon 4) (Grin2d), mRNA [NM_008172] |
KLA | 1.57 |
1.18 |
1.35 |
1.45 |
1.25 |
1.49 |
.91 |
| ATP | .92 |
.99 |
1.45 |
1.66 |
1.54 |
2.02 |
1.15 |
| KLA/ATP | 1.23 |
1.38 |
2.08 |
2.28 |
1.92 |
2.53 |
1.92 |
|
Grin3a | |
AK044171 |
10 days neonate cortex cDNA, RIKEN full-length enriched library, clone:A830097C19 product:similar to IONOTROPIC GLUTAMATE RECEPTOR NMDA subunit NR3A[Rattus norvegicus], full insert sequence. [AK044171] |
KLA | 1.06 |
1.00 |
.93 |
.95 |
.97 |
.97 |
.99 |
| ATP | .96 |
.97 |
1.02 |
.94 |
1.03 |
1.02 |
1.03 |
| KLA/ATP | 1.05 |
.96 |
1.05 |
.98 |
.94 |
1.02 |
1.03 |
|
Grin3b | |
NM_130455 |
glutamate receptor, ionotropic, NMDA3B (Grin3b), mRNA [NM_130455] |
KLA | .90 |
.92 |
.88 |
.98 |
.91 |
.91 |
.69 |
| ATP | .96 |
.93 |
.94 |
.92 |
.93 |
.84 |
.68 |
| KLA/ATP | .92 |
.88 |
.88 |
.95 |
.96 |
.88 |
.68 |
|
Grm1 | |
NM_016976 |
glutamate receptor, metabotropic 1 (Grm1), transcript variant 1, mRNA [NM_016976] |
KLA | 1.16 |
1.07 |
1.10 |
1.18 |
1.08 |
1.04 |
1.15 |
| ATP | 1.06 |
1.05 |
1.02 |
.99 |
1.00 |
1.09 |
1.02 |
| KLA/ATP | 1.04 |
1.12 |
1.06 |
1.11 |
1.10 |
1.32 |
1.35 |
|
Grm2 | |
AK015353 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4930441L02 product:unclassifiable, full insert sequence [AK015353] |
KLA | 1.01 |
1.07 |
1.07 |
1.07 |
.99 |
.97 |
.98 |
| ATP | 1.03 |
1.05 |
.96 |
1.04 |
1.02 |
.90 |
.94 |
| KLA/ATP | 1.05 |
1.08 |
1.02 |
.99 |
.94 |
.98 |
1.01 |
|
Grm2 | |
XM_001475814 |
gb|PREDICTED: Mus musculus G protein-coupled receptor, family C, group 1, member B (Grm2), mRNA [XM_001475814] |
KLA | 1.01 |
1.02 |
.94 |
.98 |
1.01 |
.99 |
.99 |
| ATP | 1.03 |
1.01 |
1.03 |
1.03 |
1.05 |
1.01 |
1.03 |
| KLA/ATP | 1.02 |
.97 |
1.05 |
1.00 |
.98 |
1.02 |
1.08 |
|
Grm3 | |
NM_181850 |
glutamate receptor, metabotropic 3 (Grm3), mRNA [NM_181850] |
KLA | .95 |
1.00 |
1.00 |
1.01 |
.96 |
.99 |
.99 |
| ATP | .97 |
1.02 |
.99 |
1.08 |
1.05 |
1.02 |
1.04 |
| KLA/ATP | 1.00 |
.98 |
.99 |
1.07 |
1.07 |
1.03 |
1.04 |
|
Grm4 | |
NM_001013385 |
glutamate receptor, metabotropic 4 (Grm4), mRNA [NM_001013385] |
KLA | .94 |
.97 |
.98 |
1.01 |
1.01 |
1.02 |
1.08 |
| ATP | .99 |
.94 |
1.03 |
.98 |
.95 |
.98 |
1.07 |
| KLA/ATP | .99 |
1.02 |
.93 |
1.00 |
1.02 |
1.03 |
1.05 |
|
Grm5 | |
NM_001081414 |
glutamate receptor, metabotropic 5 (Grm5), mRNA [NM_001081414] |
KLA | 1.04 |
1.05 |
1.04 |
1.04 |
1.02 |
1.01 |
1.05 |
| ATP | .99 |
1.02 |
1.03 |
1.01 |
.99 |
1.00 |
1.03 |
| KLA/ATP | 1.03 |
1.02 |
1.02 |
1.03 |
1.01 |
1.01 |
1.05 |
|
Grm6 | |
BC034118 |
cDNA clone IMAGE:4511841, containing frame-shift errors [BC034118] |
KLA | 1.00 |
.92 |
.99 |
1.02 |
.95 |
1.02 |
1.04 |
| ATP | 1.01 |
1.01 |
.99 |
.94 |
.94 |
.98 |
1.06 |
| KLA/ATP | .99 |
.99 |
1.01 |
1.02 |
1.00 |
.93 |
.91 |
|
Grm7 | |
NM_177328 |
glutamate receptor, metabotropic 7 (Grm7), mRNA [NM_177328] |
KLA | .97 |
1.05 |
.96 |
1.05 |
1.02 |
1.01 |
1.02 |
| ATP | 1.02 |
.99 |
1.02 |
.97 |
1.00 |
1.04 |
1.01 |
| KLA/ATP | 1.00 |
1.00 |
.96 |
1.03 |
1.02 |
1.00 |
1.02 |
|
Grm8 | |
NM_008174 |
glutamate receptor, metabotropic 8 (Grm8), mRNA [NM_008174] |
KLA | .98 |
.97 |
1.01 |
1.06 |
.99 |
.95 |
1.02 |
| ATP | 1.09 |
1.07 |
1.10 |
1.05 |
1.04 |
1.02 |
1.07 |
| KLA/ATP | 1.03 |
1.06 |
1.06 |
1.05 |
1.07 |
1.10 |
.93 |
|
Grp | |
NM_175012 |
gastrin releasing peptide (Grp), mRNA [NM_175012] |
KLA | .98 |
1.01 |
1.04 |
1.03 |
1.01 |
.95 |
1.03 |
| ATP | .98 |
1.08 |
1.00 |
.97 |
1.09 |
1.01 |
.97 |
| KLA/ATP | 1.00 |
.99 |
1.03 |
1.01 |
1.05 |
.96 |
1.02 |
|
Grpr | |
NM_008177 |
gastrin releasing peptide receptor (Grpr), mRNA [NM_008177] |
KLA | 1.00 |
.96 |
.99 |
1.03 |
.99 |
1.03 |
1.04 |
| ATP | .95 |
1.00 |
1.07 |
1.00 |
1.01 |
1.03 |
1.05 |
| KLA/ATP | .96 |
1.02 |
1.06 |
1.04 |
.93 |
1.03 |
.96 |
|
Gzma | |
NM_010370 |
granzyme A (Gzma), mRNA [NM_010370] |
KLA | 1.04 |
1.03 |
.95 |
.94 |
.99 |
.96 |
.99 |
| ATP | 1.01 |
.93 |
1.05 |
1.00 |
1.03 |
1.05 |
1.03 |
| KLA/ATP | .98 |
1.00 |
1.13 |
.96 |
1.02 |
.99 |
.99 |
|
Hcrt | |
NM_010410 |
hypocretin (Hcrt), mRNA [NM_010410] |
KLA | 1.01 |
1.05 |
1.03 |
1.06 |
1.08 |
1.16 |
1.08 |
| ATP | 1.00 |
.98 |
1.07 |
1.02 |
1.01 |
1.03 |
.98 |
| KLA/ATP | .91 |
.98 |
1.00 |
1.15 |
1.11 |
1.07 |
.93 |
|
Hcrtr1 | |
NM_198959 |
hypocretin (orexin) receptor 1 (Hcrtr1), mRNA [NM_198959] |
KLA | 1.00 |
1.05 |
.98 |
1.09 |
1.01 |
1.02 |
1.14 |
| ATP | .98 |
1.02 |
1.01 |
.98 |
1.06 |
1.05 |
.91 |
| KLA/ATP | 1.03 |
1.03 |
1.04 |
1.01 |
1.07 |
1.04 |
.98 |
|
Hcrtr2 | |
AY336084 |
orexin receptor type-2a mRNA, complete cds. [AY336084] |
KLA | .99 |
.98 |
1.03 |
.97 |
.94 |
.96 |
1.03 |
| ATP | 1.07 |
1.04 |
.98 |
1.03 |
.98 |
1.03 |
1.03 |
| KLA/ATP | .99 |
1.04 |
1.08 |
.98 |
1.00 |
.99 |
.99 |
|
Hcrtr2 | |
NM_198962 |
hypocretin (orexin) receptor 2 (Hcrtr2), mRNA [NM_198962] |
KLA | 1.05 |
.99 |
.98 |
1.04 |
1.05 |
1.02 |
1.06 |
| ATP | .99 |
1.00 |
1.02 |
.92 |
.96 |
.99 |
1.02 |
| KLA/ATP | .96 |
1.03 |
1.02 |
.94 |
1.04 |
.97 |
1.02 |
|
Hrh1 | |
NM_008285 |
histamine receptor H1 (Hrh1), mRNA [NM_008285] |
KLA | .92 |
.94 |
.84 |
.88 |
1.27 |
1.69 |
1.61 |
| ATP | 1.05 |
.97 |
.92 |
.83 |
.85 |
.97 |
1.04 |
| KLA/ATP | .86 |
.89 |
.83 |
.74 |
.87 |
1.20 |
2.84 |
|
Hrh2 | |
NM_008286 |
histamine receptor H2 (Hrh2), transcript variant 2, mRNA [NM_008286] |
KLA | 1.18 |
1.33 |
1.70 |
1.54 |
1.69 |
1.61 |
1.52 |
| ATP | .96 |
1.10 |
.98 |
1.08 |
.99 |
1.03 |
1.35 |
| KLA/ATP | 1.25 |
1.19 |
1.15 |
1.20 |
1.09 |
1.39 |
1.92 |
|
Hrh3 | |
NM_133849 |
histamine receptor H3 (Hrh3), mRNA [NM_133849] |
KLA | 1.06 |
.82 |
1.00 |
1.06 |
1.02 |
1.05 |
1.14 |
| ATP | 1.01 |
.97 |
1.02 |
1.11 |
1.03 |
1.05 |
1.06 |
| KLA/ATP | 1.04 |
1.10 |
1.02 |
1.12 |
1.11 |
.98 |
1.05 |
|
Hrh4 | |
NM_153087 |
histamine receptor H4 (Hrh4), mRNA [NM_153087] |
KLA | .99 |
1.02 |
.99 |
1.04 |
1.07 |
.94 |
.99 |
| ATP | 1.03 |
1.04 |
1.14 |
2.23 |
1.22 |
1.01 |
1.05 |
| KLA/ATP | .97 |
1.07 |
1.08 |
1.37 |
1.17 |
1.05 |
.98 |
|
Htr1a | |
NM_008308 |
5-hydroxytryptamine (serotonin) receptor 1A (Htr1a), mRNA [NM_008308] |
KLA | .94 |
.96 |
1.04 |
1.00 |
.92 |
1.00 |
1.01 |
| ATP | 1.00 |
.93 |
1.03 |
1.03 |
1.03 |
.96 |
.99 |
| KLA/ATP | .98 |
.96 |
1.09 |
1.04 |
.97 |
1.08 |
1.03 |
|
Htr1b | |
NM_010482 |
5-hydroxytryptamine (serotonin) receptor 1B (Htr1b), mRNA [NM_010482] |
KLA | 1.12 |
.98 |
1.02 |
1.08 |
1.05 |
1.03 |
.97 |
| ATP | 1.01 |
1.00 |
.93 |
1.04 |
.95 |
1.27 |
1.02 |
| KLA/ATP | .98 |
.96 |
.97 |
1.04 |
1.04 |
1.00 |
1.10 |
|
Htr1d | |
NM_008309 |
5-hydroxytryptamine (serotonin) receptor 1D (Htr1d), mRNA [NM_008309] |
KLA | .99 |
1.01 |
1.00 |
1.02 |
1.00 |
1.00 |
.95 |
| ATP | .95 |
.93 |
.99 |
1.12 |
1.01 |
1.02 |
1.03 |
| KLA/ATP | .97 |
1.00 |
1.05 |
.97 |
.95 |
.96 |
.89 |
|
Htr1f | |
NM_008310 |
5-hydroxytryptamine (serotonin) receptor 1F (Htr1f), mRNA [NM_008310] |
KLA | 1.04 |
1.02 |
1.02 |
1.08 |
.98 |
1.03 |
1.05 |
| ATP | 1.03 |
1.08 |
1.06 |
.90 |
1.01 |
1.04 |
1.14 |
| KLA/ATP | 1.01 |
1.02 |
1.13 |
1.00 |
1.11 |
.98 |
1.03 |
|
Htr2a | |
NM_172812 |
5-hydroxytryptamine (serotonin) receptor 2A (Htr2a), mRNA [NM_172812] |
KLA | 1.00 |
1.01 |
1.03 |
1.00 |
.97 |
.96 |
.99 |
| ATP | .97 |
.97 |
.95 |
1.12 |
1.41 |
.98 |
.95 |
| KLA/ATP | .92 |
1.01 |
1.07 |
1.08 |
1.03 |
.98 |
1.06 |
|
Htr2b | |
NM_008311 |
5-hydroxytryptamine (serotonin) receptor 2B (Htr2b), mRNA [NM_008311] |
KLA | .47 |
.44 |
.41 |
.46 |
.73 |
1.91 |
1.14 |
| ATP | .90 |
.92 |
.95 |
1.02 |
1.24 |
1.47 |
11.87 |
| KLA/ATP | .44 |
.43 |
.51 |
.56 |
1.05 |
4.41 |
10.84 |
|
Htr2c | |
AK086348 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930023E13 product:5-hydroxytryptamine (serotonin) receptor 2C, full insert sequence. [AK086348] |
KLA | 1.01 |
1.01 |
1.00 |
1.03 |
1.03 |
1.04 |
1.04 |
| ATP | 1.01 |
1.00 |
1.00 |
1.04 |
1.02 |
1.03 |
.99 |
| KLA/ATP | .99 |
1.02 |
.96 |
1.07 |
1.03 |
1.06 |
1.06 |
|
Htr2c | |
NM_008312 |
5-hydroxytryptamine (serotonin) receptor 2C (Htr2c), mRNA [NM_008312] |
KLA | 1.03 |
1.08 |
1.00 |
1.05 |
1.02 |
1.02 |
.98 |
| ATP | .96 |
1.02 |
1.01 |
1.05 |
.98 |
.99 |
1.03 |
| KLA/ATP | 1.00 |
1.00 |
1.04 |
.97 |
.96 |
.96 |
.98 |
|
Htr4 | |
NM_008313 |
5 hydroxytryptamine (serotonin) receptor 4 (Htr4), mRNA [NM_008313] |
KLA | 1.02 |
1.05 |
.99 |
.99 |
1.01 |
.99 |
1.08 |
| ATP | .98 |
1.04 |
1.04 |
1.06 |
.96 |
1.02 |
1.06 |
| KLA/ATP | 1.00 |
.98 |
.97 |
1.03 |
1.02 |
1.08 |
1.00 |
|
Htr5a | |
NM_008314 |
5-hydroxytryptamine (serotonin) receptor 5A (Htr5a), mRNA [NM_008314] |
KLA | 1.08 |
1.01 |
1.14 |
1.10 |
1.13 |
1.04 |
1.08 |
| ATP | 1.09 |
.98 |
.96 |
.97 |
1.04 |
1.00 |
1.03 |
| KLA/ATP | 1.12 |
1.08 |
1.12 |
.99 |
1.00 |
1.03 |
.98 |
|
Htr5b | |
NM_010483 |
5-hydroxytryptamine (serotonin) receptor 5B (Htr5b), mRNA [NM_010483] |
KLA | .99 |
.98 |
1.01 |
.98 |
.97 |
.99 |
.98 |
| ATP | .95 |
1.00 |
1.01 |
1.01 |
1.01 |
1.06 |
.94 |
| KLA/ATP | .97 |
1.00 |
1.05 |
1.03 |
1.00 |
.93 |
1.06 |
|
Htr6 | |
NM_021358 |
5-hydroxytryptamine (serotonin) receptor 6 (Htr6), mRNA [NM_021358] |
KLA | 1.04 |
1.01 |
1.01 |
1.06 |
1.05 |
.98 |
.97 |
| ATP | 1.00 |
1.03 |
.96 |
.96 |
1.02 |
.96 |
1.02 |
| KLA/ATP | .93 |
.94 |
1.03 |
1.03 |
.91 |
1.00 |
.91 |
|
Htr7 | |
NM_008315 |
5-hydroxytryptamine (serotonin) receptor 7 (Htr7), mRNA [NM_008315] |
KLA | 1.07 |
.91 |
1.03 |
1.05 |
1.02 |
1.07 |
.97 |
| ATP | .97 |
1.02 |
1.00 |
1.03 |
1.05 |
1.05 |
.99 |
| KLA/ATP | 1.03 |
1.03 |
1.10 |
.99 |
.99 |
1.09 |
1.25 |
|
Kiss1r | |
NM_053244 |
KISS1 receptor (Kiss1r), mRNA [NM_053244] |
KLA | .91 |
.93 |
.93 |
.94 |
.98 |
1.04 |
.95 |
| ATP | 1.06 |
.93 |
.98 |
.84 |
.84 |
.82 |
1.00 |
| KLA/ATP | .91 |
.96 |
.97 |
.93 |
.85 |
.98 |
.98 |
|
Lep | |
NM_008493 |
leptin (Lep), mRNA [NM_008493] |
KLA | .99 |
1.00 |
1.00 |
.99 |
.99 |
.99 |
1.00 |
| ATP | 1.01 |
1.00 |
.98 |
1.01 |
1.01 |
.99 |
.98 |
| KLA/ATP | 1.01 |
1.02 |
1.01 |
.97 |
1.00 |
1.00 |
.99 |
|
Lepr | |
NM_001122899 |
leptin receptor (Lepr), transcript variant 3, mRNA [NM_001122899] |
KLA | .98 |
1.05 |
1.00 |
1.03 |
.98 |
1.01 |
1.10 |
| ATP | 1.07 |
.99 |
.98 |
1.06 |
1.08 |
1.02 |
1.02 |
| KLA/ATP | 1.07 |
1.03 |
.99 |
1.11 |
1.03 |
1.12 |
.98 |
|
Lepr | |
NM_010704 |
leptin receptor (Lepr), transcript variant 2, mRNA [NM_010704] |
KLA | 1.01 |
1.01 |
1.03 |
.99 |
1.01 |
1.02 |
.99 |
| ATP | .98 |
1.00 |
1.02 |
1.02 |
1.02 |
1.02 |
1.01 |
| KLA/ATP | 1.00 |
1.00 |
1.02 |
1.03 |
1.00 |
1.01 |
.98 |
|
Lgr4 | |
AK052660 |
0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630016D21 product:unclassifiable, full insert sequence. [AK052660] |
KLA | .98 |
1.00 |
.94 |
.97 |
1.01 |
1.00 |
.98 |
| ATP | .96 |
1.00 |
1.01 |
.97 |
.99 |
1.01 |
.96 |
| KLA/ATP | 1.02 |
1.03 |
.99 |
1.00 |
1.00 |
.99 |
.92 |
|
Lgr4 | |
NM_172671 |
leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4), mRNA [NM_172671] |
KLA | 1.09 |
1.17 |
1.09 |
1.03 |
1.01 |
.92 |
.87 |
| ATP | 1.03 |
1.03 |
.97 |
1.03 |
1.02 |
1.52 |
.95 |
| KLA/ATP | 1.08 |
1.09 |
1.06 |
1.05 |
1.01 |
1.16 |
1.02 |
|
Lgr5 | |
AK047873 |
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130018C02 product:G protein-coupled receptor 49, full insert sequence [AK047873] |
KLA | .97 |
.95 |
1.03 |
1.06 |
.96 |
1.01 |
.98 |
| ATP | 1.00 |
1.00 |
1.06 |
.90 |
1.05 |
.99 |
.98 |
| KLA/ATP | 1.02 |
.96 |
.98 |
.93 |
.98 |
.97 |
1.01 |
|
Lgr5 | |
NM_010195 |
leucine rich repeat containing G protein coupled receptor 5 (Lgr5), mRNA [NM_010195] |
KLA | 1.01 |
1.03 |
1.02 |
1.03 |
.99 |
1.03 |
.90 |
| ATP | 1.01 |
1.00 |
.98 |
1.05 |
.93 |
1.02 |
.96 |
| KLA/ATP | 1.04 |
1.06 |
.97 |
1.04 |
1.04 |
1.00 |
.70 |
|
Lhb | |
AK138425 |
adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230101A12 product:luteinizing hormone beta, full insert sequence [AK138425] |
KLA | 1.06 |
1.01 |
1.02 |
.98 |
1.00 |
1.07 |
.91 |
| ATP | 1.02 |
1.04 |
.91 |
.96 |
.90 |
1.05 |
.95 |
| KLA/ATP | .98 |
.96 |
1.01 |
1.03 |
1.04 |
1.00 |
1.09 |
|
Lhb | |
NM_008497 |
luteinizing hormone beta (Lhb), mRNA [NM_008497] |
KLA | 1.16 |
1.26 |
1.24 |
1.20 |
1.29 |
1.29 |
1.23 |
| ATP | 1.01 |
1.01 |
1.12 |
1.19 |
1.22 |
1.21 |
1.23 |
| KLA/ATP | 1.12 |
1.12 |
1.33 |
1.53 |
1.47 |
1.42 |
1.44 |
|
Lhcgr | |
NM_013582 |
luteinizing hormone/choriogonadotropin receptor (Lhcgr), mRNA [NM_013582] |
KLA | .98 |
1.06 |
.99 |
.95 |
1.01 |
1.00 |
1.04 |
| ATP | 1.01 |
.95 |
1.00 |
1.04 |
1.00 |
1.03 |
1.00 |
| KLA/ATP | 1.04 |
1.02 |
.97 |
1.01 |
1.03 |
1.04 |
.98 |
|
Lpar2 | |
NM_020028 |
lysophosphatidic acid receptor 2 (Lpar2), mRNA [NM_020028] |
KLA | .80 |
.84 |
.81 |
.80 |
.72 |
.71 |
.78 |
| ATP | 1.08 |
1.02 |
1.00 |
1.14 |
1.02 |
.82 |
.75 |
| KLA/ATP | .98 |
.82 |
.87 |
.81 |
1.06 |
.76 |
.69 |
|
Lpar3 | |
NM_022983 |
lysophosphatidic acid receptor 3 (Lpar3), mRNA [NM_022983] |
KLA | 1.04 |
1.04 |
1.09 |
1.01 |
.96 |
.96 |
.97 |
| ATP | .98 |
.97 |
.94 |
1.07 |
1.06 |
1.04 |
.98 |
| KLA/ATP | 1.05 |
1.14 |
1.02 |
1.06 |
1.24 |
1.06 |
1.01 |
|
Lpar4 | |
NM_175271 |
lysophosphatidic acid receptor 4 (Lpar4), mRNA [NM_175271] |
KLA | 1.15 |
1.14 |
1.12 |
1.07 |
.98 |
1.00 |
1.04 |
| ATP | 1.06 |
1.00 |
1.07 |
.98 |
.94 |
.99 |
.94 |
| KLA/ATP | 1.15 |
1.17 |
1.14 |
1.13 |
1.05 |
1.08 |
1.01 |
|
Ltb4r1 | |
NM_008519 |
leukotriene B4 receptor 1 (Ltb4r1), mRNA [NM_008519] |
KLA | .81 |
.83 |
.81 |
.92 |
.97 |
.98 |
1.21 |
| ATP | 1.07 |
1.10 |
1.24 |
1.29 |
.94 |
1.24 |
5.17 |
| KLA/ATP | .77 |
.83 |
1.06 |
1.06 |
.99 |
1.10 |
3.24 |
|
Ltb4r2 | |
NM_020490 |
leukotriene B4 receptor 2 (Ltb4r2), mRNA [NM_020490] |
KLA | .97 |
1.01 |
1.01 |
.99 |
1.03 |
1.04 |
1.01 |
| ATP | 1.02 |
.91 |
1.07 |
1.01 |
1.08 |
1.03 |
1.01 |
| KLA/ATP | .95 |
1.01 |
1.00 |
1.03 |
1.04 |
1.01 |
1.03 |
|
M31654 | |
M31654 |
gb|Mouse growth hormone-releasing hormone mRNA, complete cds. [M31654] |
KLA | .94 |
.96 |
.97 |
.95 |
.85 |
.89 |
.97 |
| ATP | .98 |
.94 |
.99 |
.95 |
.93 |
.93 |
.92 |
| KLA/ATP | .97 |
.96 |
1.04 |
.97 |
.93 |
.96 |
.92 |
|
Mas1 | |
NM_008552 |
MAS1 oncogene (Mas1), mRNA [NM_008552] |
KLA | 1.01 |
.96 |
1.01 |
1.00 |
.99 |
1.05 |
1.01 |
| ATP | 1.00 |
.97 |
.99 |
1.00 |
.99 |
.99 |
1.01 |
| KLA/ATP | .98 |
1.04 |
1.01 |
1.03 |
1.00 |
.94 |
.84 |
|
Mc1r | |
NM_008559 |
melanocortin 1 receptor (Mc1r), mRNA [NM_008559] |
KLA | 1.09 |
.97 |
1.02 |
1.04 |
.96 |
.99 |
.97 |
| ATP | 1.02 |
1.04 |
.96 |
1.06 |
.92 |
.96 |
1.03 |
| KLA/ATP | 1.04 |
1.09 |
.92 |
1.03 |
1.02 |
.98 |
1.01 |
|
Mc2r | |
NM_008560 |
melanocortin 2 receptor (Mc2r), mRNA [NM_008560] |
KLA | 1.08 |
1.02 |
1.03 |
1.05 |
1.10 |
1.07 |
1.05 |
| ATP | 1.05 |
1.03 |
1.16 |
.95 |
.95 |
1.00 |
1.01 |
| KLA/ATP | .92 |
1.02 |
1.14 |
.97 |
.97 |
.96 |
.98 |
|
Mc3r | |
NM_008561 |
melanocortin 3 receptor (Mc3r), mRNA [NM_008561] |
KLA | 1.75 |
2.01 |
2.04 |
1.64 |
1.75 |
1.63 |
1.62 |
| ATP | 1.02 |
1.14 |
1.21 |
1.71 |
1.38 |
1.46 |
1.52 |
| KLA/ATP | 1.91 |
1.99 |
1.87 |
3.16 |
2.13 |
1.97 |
2.31 |
|
Mc4r | |
NM_016977 |
melanocortin 4 receptor (Mc4r), mRNA [NM_016977] |
KLA | 1.11 |
1.08 |
1.14 |
1.31 |
1.10 |
1.20 |
1.06 |
| ATP | 1.02 |
.98 |
1.21 |
1.07 |
1.10 |
1.02 |
1.05 |
| KLA/ATP | 1.11 |
1.12 |
1.24 |
1.17 |
1.19 |
1.00 |
1.02 |
|
Mc5r | |
NM_013596 |
melanocortin 5 receptor (Mc5r), mRNA [NM_013596] |
KLA | 1.01 |
.94 |
1.04 |
1.04 |
1.08 |
1.00 |
.98 |
| ATP | 1.03 |
1.02 |
1.01 |
1.00 |
.96 |
1.03 |
1.00 |
| KLA/ATP | 1.06 |
.98 |
1.03 |
1.04 |
1.08 |
1.01 |
.97 |
|
Mchr1 | |
NM_145132 |
melanin-concentrating hormone receptor 1 (Mchr1), mRNA [NM_145132] |
KLA | 1.19 |
1.16 |
1.18 |
1.27 |
1.11 |
1.31 |
1.19 |
| ATP | 1.10 |
1.04 |
1.24 |
1.16 |
1.27 |
1.31 |
1.05 |
| KLA/ATP | 1.14 |
1.20 |
1.32 |
1.40 |
1.43 |
1.42 |
1.25 |
|
Mm.20122
| |
21703877 |
Unknown |
KLA | .95 |
.99 |
1.04 |
.93 |
.93 |
1.03 |
.94 |
| ATP | 1.01 |
.94 |
.92 |
1.10 |
.99 |
.96 |
.85 |
| KLA/ATP | .96 |
.99 |
.96 |
1.16 |
1.05 |
1.02 |
.88 |
|
Mm.22329
| |
160298175 |
Unknown |
KLA | .41 |
.41 |
.33 |
.42 |
.40 |
.53 |
.84 |
| ATP | .91 |
.94 |
1.02 |
.97 |
.70 |
.64 |
.72 |
| KLA/ATP | .37 |
.36 |
.45 |
.41 |
.55 |
.58 |
.53 |
|
Mm.23519 3 | |
34147202 |
Unknown |
KLA | .46 |
.45 |
.56 |
.99 |
1.53 |
1.74 |
1.00 |
| ATP | .96 |
.93 |
.82 |
.69 |
.46 |
.51 |
1.36 |
| KLA/ATP | .44 |
.41 |
.35 |
.38 |
.43 |
.49 |
1.13 |
|
Mm.23957 0 | |
141802432 |
Unknown |
KLA | .38 |
.34 |
.26 |
.32 |
.34 |
.48 |
.60 |
| ATP | .88 |
.96 |
1.17 |
.89 |
.38 |
.35 |
.71 |
| KLA/ATP | .36 |
.39 |
.44 |
.38 |
.35 |
.26 |
.66 |
|
Mm.24060 7 | |
162951825 |
Unknown |
KLA | .94 |
.96 |
.91 |
1.02 |
.90 |
.84 |
.97 |
| ATP | 1.08 |
1.01 |
1.08 |
.95 |
1.04 |
.89 |
.89 |
| KLA/ATP | .93 |
1.01 |
1.05 |
.92 |
.84 |
.88 |
.76 |
|
Mm.2408 | |
147904678 |
Unknown |
KLA | .92 |
.85 |
1.02 |
1.30 |
1.31 |
1.65 |
1.62 |
| ATP | .92 |
.87 |
.90 |
.60 |
.44 |
.36 |
1.61 |
| KLA/ATP | .87 |
.78 |
.82 |
.60 |
.66 |
.59 |
1.06 |
|
Mm.28757 2 | |
163965437 |
Unknown |
KLA | .78 |
.80 |
1.02 |
1.85 |
2.49 |
1.68 |
2.10 |
| ATP | .83 |
.79 |
1.13 |
.86 |
3.55 |
6.26 |
1.82 |
| KLA/ATP | .69 |
.68 |
.88 |
1.30 |
16.81 |
15.38 |
3.29 |
|
Mm.29111 0 | |
94362689 |
Unknown |
KLA | 1.07 |
1.02 |
.99 |
1.00 |
1.03 |
1.01 |
1.02 |
| ATP | .99 |
.98 |
1.01 |
.97 |
1.08 |
1.08 |
1.07 |
| KLA/ATP | 1.00 |
1.06 |
1.03 |
1.01 |
1.08 |
1.05 |
.97 |
|
Mm.32259 4 | |
144922605 |
Unknown |
KLA | 1.02 |
1.03 |
.98 |
.98 |
.95 |
1.00 |
1.02 |
| ATP | 1.01 |
.98 |
1.08 |
1.01 |
1.04 |
1.01 |
.97 |
| KLA/ATP | .97 |
1.08 |
1.04 |
1.02 |
1.00 |
1.01 |
1.03 |
|
Mm.33407 4 | |
124487260 |
Unknown |
KLA | 1.01 |
1.02 |
.98 |
.98 |
.92 |
.98 |
1.05 |
| ATP | .98 |
.95 |
.98 |
1.06 |
1.06 |
.94 |
.98 |
| KLA/ATP | 1.03 |
1.02 |
1.10 |
1.07 |
1.05 |
1.02 |
1.00 |
|
Mm.35830 9 | |
158517802 |
Unknown |
KLA | .63 |
.61 |
.71 |
.69 |
.91 |
1.05 |
.78 |
| ATP | 1.00 |
.94 |
1.06 |
.83 |
5.04 |
3.12 |
.78 |
| KLA/ATP | .62 |
.59 |
.86 |
.69 |
4.90 |
2.07 |
1.10 |
|
Mm.37724 1 | |
42476093 |
Unknown |
KLA | 1.05 |
1.03 |
.99 |
1.04 |
1.00 |
.99 |
.97 |
| ATP | .96 |
1.09 |
1.11 |
1.08 |
1.07 |
1.05 |
.99 |
| KLA/ATP | 1.08 |
1.03 |
1.08 |
.96 |
1.03 |
1.06 |
1.01 |
|
Mm.37909 5 | |
142358944 |
Unknown |
KLA | 1.03 |
1.10 |
1.11 |
1.07 |
1.12 |
1.15 |
1.09 |
| ATP | 1.01 |
1.03 |
1.20 |
1.24 |
1.34 |
1.21 |
1.12 |
| KLA/ATP | 1.17 |
1.13 |
1.23 |
1.33 |
1.40 |
1.28 |
1.09 |
|
Mm.38317 1 | |
9506412 |
Unknown |
KLA | .98 |
1.08 |
.95 |
.98 |
1.01 |
1.09 |
1.13 |
| ATP | 1.04 |
1.03 |
1.03 |
1.02 |
.95 |
.93 |
1.00 |
| KLA/ATP | .98 |
1.06 |
.98 |
1.02 |
.91 |
.91 |
1.10 |
|
Mm.40085
| |
16716382 |
Unknown |
KLA | 1.01 |
.96 |
.97 |
.94 |
.99 |
.95 |
.97 |
| ATP | 1.00 |
.89 |
.91 |
.97 |
1.05 |
1.02 |
.96 |
| KLA/ATP | 1.04 |
.97 |
1.01 |
.97 |
1.03 |
.98 |
.95 |
|
Mm.40715 2 | |
156766087 |
Unknown |
KLA | .98 |
1.00 |
1.03 |
1.03 |
.98 |
1.01 |
.96 |
| ATP | 1.03 |
1.01 |
1.00 |
.97 |
1.00 |
1.04 |
1.06 |
| KLA/ATP | .96 |
.98 |
1.03 |
1.02 |
1.03 |
1.03 |
1.02 |
|
Mm.42026
| |
84781761 |
Unknown |
KLA | .55 |
.55 |
.60 |
.65 |
.79 |
1.01 |
.87 |
| ATP | .97 |
.99 |
1.03 |
.91 |
.56 |
.43 |
.56 |
| KLA/ATP | .60 |
.58 |
.68 |
.58 |
.85 |
.96 |
1.13 |
|
Mm.44009 5 | |
166158133 |
Unknown |
KLA | .99 |
1.03 |
1.07 |
1.00 |
1.07 |
1.07 |
1.06 |
| ATP | .98 |
1.01 |
.98 |
.94 |
1.06 |
.96 |
.95 |
| KLA/ATP | 1.04 |
1.05 |
1.00 |
.97 |
1.06 |
.99 |
.95 |
|
Mm.4630 | |
144227232 |
Unknown |
KLA | .80 |
.84 |
.78 |
.81 |
.79 |
.88 |
2.00 |
| ATP | .95 |
.87 |
1.02 |
.83 |
1.79 |
2.79 |
2.35 |
| KLA/ATP | .84 |
.79 |
.79 |
.76 |
.89 |
1.40 |
2.76 |
|
Mm.4716 | |
162135953 |
Unknown |
KLA | 1.04 |
1.03 |
.98 |
.99 |
.98 |
.99 |
1.08 |
| ATP | 1.01 |
1.06 |
1.08 |
1.07 |
1.09 |
1.03 |
1.05 |
| KLA/ATP | .99 |
.93 |
1.03 |
1.14 |
1.03 |
1.09 |
1.00 |
|
Mm.47319 5 | |
124358929 |
Unknown |
KLA | 1.13 |
1.14 |
1.12 |
1.11 |
1.06 |
1.03 |
1.01 |
| ATP | 1.05 |
1.01 |
.94 |
1.06 |
1.06 |
1.04 |
.98 |
| KLA/ATP | 1.15 |
1.14 |
1.20 |
1.15 |
1.06 |
.93 |
1.01 |
|
Mm.5243 | |
124244063 |
Unknown |
KLA | 1.06 |
1.04 |
1.06 |
.98 |
1.03 |
1.06 |
1.04 |
| ATP | 1.01 |
.93 |
1.02 |
1.08 |
.97 |
1.05 |
1.03 |
| KLA/ATP | 1.16 |
1.05 |
1.11 |
1.01 |
1.04 |
1.06 |
1.10 |
|
Mm.54161
| |
164607143 |
Unknown |
KLA | .97 |
.99 |
1.00 |
.98 |
.95 |
.98 |
.94 |
| ATP | 1.01 |
.99 |
1.06 |
1.07 |
1.02 |
.95 |
.98 |
| KLA/ATP | .93 |
1.04 |
1.07 |
.96 |
.90 |
.95 |
.94 |
|
Mm.89984
| |
6755930 |
Unknown |
KLA | 1.08 |
.97 |
.96 |
1.02 |
1.02 |
1.03 |
.99 |
| ATP | .98 |
1.00 |
.89 |
.95 |
.98 |
.97 |
1.00 |
| KLA/ATP | .94 |
.96 |
1.04 |
1.03 |
1.00 |
1.00 |
1.00 |
|
Mtnr1a | |
NM_008639 |
melatonin receptor 1A (Mtnr1a), mRNA [NM_008639] |
KLA | .99 |
1.04 |
1.04 |
1.05 |
1.02 |
1.02 |
1.02 |
| ATP | 1.03 |
1.00 |
.99 |
1.01 |
1.06 |
.94 |
1.02 |
| KLA/ATP | 1.02 |
1.00 |
1.03 |
1.05 |
.98 |
1.07 |
.98 |
|
Mtnr1b | |
NM_145712 |
melatonin receptor 1B (Mtnr1b), mRNA [NM_145712] |
KLA | 1.01 |
.94 |
.98 |
1.02 |
1.03 |
.95 |
1.09 |
| ATP | .96 |
1.02 |
1.03 |
1.01 |
1.02 |
.97 |
.95 |
| KLA/ATP | .96 |
1.01 |
.98 |
.94 |
.96 |
.93 |
1.00 |
|
Nmb | |
NM_026523 |
neuromedin B (Nmb), mRNA [NM_026523] |
KLA | 1.19 |
1.07 |
1.12 |
1.19 |
1.26 |
1.15 |
.73 |
| ATP | .99 |
.82 |
1.27 |
1.20 |
2.74 |
1.89 |
1.25 |
| KLA/ATP | 1.09 |
1.05 |
1.40 |
1.27 |
3.04 |
1.98 |
1.39 |
|
Nmbr | |
NM_008703 |
neuromedin B receptor (Nmbr), mRNA [NM_008703] |
KLA | .98 |
.98 |
1.04 |
1.03 |
.96 |
1.05 |
.96 |
| ATP | 1.00 |
1.00 |
1.00 |
.98 |
1.05 |
1.01 |
.97 |
| KLA/ATP | 1.04 |
.99 |
1.02 |
1.02 |
1.01 |
1.06 |
.96 |
|
Nmu | |
NM_019515 |
neuromedin U (Nmu), mRNA [NM_019515] |
KLA | .99 |
1.04 |
.94 |
1.05 |
.99 |
1.08 |
.98 |
| ATP | 1.02 |
.99 |
1.03 |
1.11 |
1.20 |
1.23 |
1.38 |
| KLA/ATP | 1.02 |
1.01 |
.98 |
1.05 |
1.29 |
1.18 |
1.22 |
|
Nmur1 | |
NM_010341 |
neuromedin U receptor 1 (Nmur1), mRNA [NM_010341] |
KLA | 1.10 |
.97 |
1.08 |
1.13 |
1.18 |
1.12 |
1.17 |
| ATP | .98 |
.97 |
.99 |
1.06 |
.96 |
1.08 |
1.48 |
| KLA/ATP | 1.13 |
1.12 |
1.02 |
1.01 |
1.01 |
1.09 |
1.40 |
|
Nmur2 | |
NM_153079 |
neuromedin U receptor 2 (Nmur2), mRNA [NM_153079] |
KLA | 1.00 |
1.01 |
1.07 |
1.00 |
1.06 |
1.03 |
.95 |
| ATP | 1.04 |
.97 |
.99 |
.95 |
.99 |
1.04 |
1.07 |
| KLA/ATP | 1.00 |
.97 |
1.05 |
.97 |
.83 |
1.01 |
1.08 |
|
Npb | |
NM_153288 |
neuropeptide B (Npb), mRNA [NM_153288] |
KLA | .91 |
.82 |
.81 |
.79 |
.81 |
.79 |
.85 |
| ATP | 1.07 |
1.10 |
.77 |
.78 |
.92 |
.75 |
.64 |
| KLA/ATP | .89 |
.85 |
.73 |
.78 |
.89 |
.82 |
.73 |
|
Npbwr1 | |
AK138357 |
adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230077K02 product:similar to Neuropeptides B [AK138357] |
KLA | .97 |
.98 |
.98 |
1.02 |
1.07 |
1.06 |
1.04 |
| ATP | 1.04 |
1.01 |
1.01 |
.94 |
.98 |
.98 |
1.04 |
| KLA/ATP | 1.01 |
1.03 |
1.14 |
1.02 |
.99 |
1.05 |
1.00 |
|
Npff | |
NM_018787 |
neuropeptide FF-amide peptide precursor (Npff), mRNA [NM_018787] |
KLA | 1.54 |
1.49 |
1.50 |
1.47 |
1.56 |
1.38 |
1.38 |
| ATP | 1.21 |
1.15 |
1.41 |
1.70 |
2.44 |
1.70 |
1.05 |
| KLA/ATP | 1.75 |
1.67 |
1.95 |
1.77 |
2.85 |
2.08 |
1.69 |
|
Npffr1 | |
XM_137119 |
gb|PREDICTED: Mus musculus neuropeptide FF receptor 1 (Npffr1), mRNA [XM_137119] |
KLA | 1.02 |
1.03 |
1.01 |
1.06 |
1.02 |
.98 |
1.04 |
| ATP | 1.04 |
.99 |
.87 |
1.00 |
1.01 |
1.08 |
1.05 |
| KLA/ATP | .96 |
1.04 |
.98 |
1.01 |
1.04 |
.90 |
.99 |
|
Npffr2 | |
NM_133192 |
neuropeptide FF receptor 2 (Npffr2), mRNA [NM_133192] |
KLA | .96 |
1.00 |
1.01 |
.97 |
1.02 |
.95 |
1.01 |
| ATP | 1.04 |
.98 |
.97 |
1.01 |
.99 |
1.04 |
.96 |
| KLA/ATP | .99 |
.96 |
.99 |
.95 |
.96 |
1.01 |
.96 |
|
Npy | |
NM_023456 |
neuropeptide Y (Npy), mRNA [NM_023456] |
KLA | 1.20 |
1.09 |
1.29 |
1.31 |
1.37 |
1.42 |
1.83 |
| ATP | 1.18 |
1.35 |
1.22 |
2.59 |
2.67 |
2.65 |
6.39 |
| KLA/ATP | 1.37 |
1.50 |
1.23 |
2.29 |
2.12 |
2.71 |
6.93 |
|
Npy1r | |
NM_010934 |
neuropeptide Y receptor Y1 (Npy1r), mRNA [NM_010934] |
KLA | .95 |
.92 |
1.04 |
.98 |
.98 |
.91 |
.98 |
| ATP | 1.00 |
1.01 |
.85 |
.96 |
.98 |
.90 |
.99 |
| KLA/ATP | .96 |
1.05 |
1.06 |
.87 |
1.06 |
.97 |
.93 |
|
Npy2r | |
NM_008731 |
neuropeptide Y receptor Y2 (Npy2r), mRNA [NM_008731] |
KLA | 1.07 |
1.09 |
.99 |
1.04 |
.97 |
.91 |
1.00 |
| ATP | 1.04 |
1.04 |
1.01 |
1.04 |
.99 |
.98 |
.98 |
| KLA/ATP | .98 |
1.05 |
.95 |
1.01 |
.92 |
.97 |
.97 |
|
Npy5r | |
NM_016708 |
neuropeptide Y receptor Y5 (Npy5r), mRNA [NM_016708] |
KLA | .99 |
.99 |
1.00 |
1.02 |
1.11 |
.97 |
1.02 |
| ATP | 1.02 |
1.03 |
.99 |
1.01 |
1.02 |
1.04 |
.99 |
| KLA/ATP | 1.00 |
.96 |
.96 |
.98 |
1.05 |
1.08 |
1.02 |
|
Npy6r | |
NM_010935 |
neuropeptide Y receptor Y6 (Npy6r), mRNA [NM_010935] |
KLA | 1.00 |
1.02 |
1.00 |
1.00 |
1.07 |
1.07 |
1.04 |
| ATP | 1.00 |
1.02 |
1.01 |
1.07 |
1.01 |
.97 |
1.04 |
| KLA/ATP | 1.02 |
.98 |
.96 |
1.12 |
1.06 |
1.16 |
.98 |
|
Nr3c1 | |
NM_008173 |
nuclear receptor subfamily 3, group C, member 1 (Nr3c1), mRNA [NM_008173] |
KLA | 2.76 |
2.90 |
3.44 |
2.94 |
2.90 |
2.08 |
1.49 |
| ATP | 1.10 |
1.26 |
1.11 |
1.22 |
1.69 |
2.11 |
1.22 |
| KLA/ATP | 3.00 |
3.06 |
2.48 |
4.07 |
2.27 |
2.58 |
2.95 |
|
Nts | |
NM_024435 |
neurotensin (Nts), mRNA [NM_024435] |
KLA | 1.26 |
1.30 |
1.27 |
1.32 |
1.20 |
1.34 |
1.26 |
| ATP | 1.07 |
1.05 |
1.11 |
1.10 |
1.19 |
1.13 |
1.47 |
| KLA/ATP | 1.28 |
1.26 |
1.36 |
1.40 |
1.45 |
1.88 |
1.91 |
|
Ntsr1 | |
NM_018766 |
neurotensin receptor 1 (Ntsr1), mRNA [NM_018766] |
KLA | 1.04 |
.98 |
.97 |
1.04 |
1.01 |
.98 |
.99 |
| ATP | .96 |
.99 |
.98 |
1.00 |
.94 |
.99 |
1.04 |
| KLA/ATP | .95 |
.95 |
1.06 |
.99 |
1.00 |
.93 |
.95 |
|
Ntsr2 | |
NM_008747 |
neurotensin receptor 2 (Ntsr2), mRNA [NM_008747] |
KLA | .97 |
1.03 |
1.01 |
1.03 |
1.04 |
1.02 |
1.07 |
| ATP | 1.00 |
1.07 |
1.00 |
1.05 |
1.01 |
1.01 |
1.04 |
| KLA/ATP | 1.01 |
.94 |
1.00 |
1.07 |
1.03 |
1.03 |
1.02 |
|
Oprd1 | |
NM_013622 |
opioid receptor, delta 1 (Oprd1), mRNA [NM_013622] |
KLA | .97 |
.98 |
1.10 |
1.01 |
.98 |
1.11 |
1.07 |
| ATP | 1.05 |
.99 |
1.05 |
1.04 |
1.06 |
1.00 |
.95 |
| KLA/ATP | 1.05 |
1.03 |
.89 |
1.13 |
1.11 |
1.18 |
.97 |
|
Oprk1 | |
NM_011011 |
opioid receptor, kappa 1 (Oprk1), mRNA [NM_011011] |
KLA | .96 |
1.02 |
1.00 |
.99 |
1.00 |
1.04 |
1.01 |
| ATP | 1.01 |
.99 |
.98 |
1.05 |
1.02 |
1.00 |
1.04 |
| KLA/ATP | .98 |
.94 |
.97 |
1.05 |
1.02 |
.99 |
1.03 |
|
Oprl1 | |
NM_011012 |
opioid receptor-like 1 (Oprl1), mRNA [NM_011012] |
KLA | 1.49 |
1.33 |
1.24 |
1.25 |
1.18 |
1.19 |
1.11 |
| ATP | 1.04 |
1.12 |
1.12 |
1.10 |
1.05 |
1.09 |
1.04 |
| KLA/ATP | 1.34 |
1.36 |
1.69 |
1.62 |
1.17 |
1.08 |
1.04 |
|
Oprm1 | |
NM_001039652 |
opioid receptor, mu 1 (Oprm1), mRNA [NM_001039652] |
KLA | .98 |
1.04 |
.94 |
.96 |
.93 |
.94 |
1.03 |
| ATP | .89 |
.92 |
1.06 |
.98 |
1.00 |
1.04 |
1.01 |
| KLA/ATP | .94 |
.97 |
1.05 |
1.00 |
1.02 |
1.01 |
1.00 |
|
Oxt | |
NM_011025 |
oxytocin (Oxt), mRNA [NM_011025] |
KLA | 1.07 |
1.11 |
1.14 |
1.22 |
1.15 |
1.13 |
1.10 |
| ATP | .95 |
.97 |
1.35 |
1.69 |
1.46 |
1.24 |
1.08 |
| KLA/ATP | 1.04 |
1.09 |
1.29 |
1.28 |
1.46 |
1.54 |
1.29 |
|
Oxtr | |
D86599 |
gb|Mus sp. mRNA for oxytocin receptor, complete cds. [D86599] |
KLA | 1.06 |
.99 |
1.04 |
1.10 |
1.01 |
.98 |
1.02 |
| ATP | 1.07 |
1.04 |
1.06 |
.96 |
1.02 |
1.01 |
1.00 |
| KLA/ATP | 1.01 |
1.00 |
.79 |
1.04 |
1.02 |
.99 |
1.01 |
|
Oxtr | |
NM_001081147 |
oxytocin receptor (Oxtr), mRNA [NM_001081147] |
KLA | 1.00 |
1.00 |
.99 |
.95 |
.99 |
1.00 |
.99 |
| ATP | 1.06 |
.99 |
1.00 |
1.01 |
.96 |
.97 |
1.03 |
| KLA/ATP | .94 |
1.08 |
1.00 |
1.00 |
.94 |
.94 |
.98 |
|
P2rx1 | |
NM_008771 |
purinergic receptor P2X, ligand-gated ion channel, 1 (P2rx1), mRNA [NM_008771] |
KLA | .98 |
1.02 |
1.06 |
1.04 |
1.03 |
.94 |
.97 |
| ATP | 1.00 |
.97 |
1.01 |
.95 |
.99 |
1.05 |
1.03 |
| KLA/ATP | 1.08 |
1.00 |
1.03 |
.98 |
.92 |
1.01 |
1.09 |
|
P2rx2 | |
NM_153400 |
purinergic receptor P2X, ligand-gated ion channel, 2 (P2rx2), mRNA [NM_153400] |
KLA | 1.15 |
1.07 |
1.12 |
1.19 |
1.18 |
1.20 |
.99 |
| ATP | .97 |
1.09 |
1.30 |
1.43 |
1.29 |
1.17 |
1.07 |
| KLA/ATP | 1.15 |
1.13 |
1.45 |
1.53 |
1.38 |
1.31 |
1.22 |
|
P2rx3 | |
AK053021 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930017N16 product:hypothetical protein, full insert sequence. [AK053021] |
KLA | .97 |
.96 |
1.03 |
1.04 |
1.02 |
1.00 |
1.05 |
| ATP | 1.00 |
1.02 |
1.00 |
1.03 |
1.01 |
.96 |
1.02 |
| KLA/ATP | .96 |
1.04 |
.96 |
.91 |
.98 |
1.04 |
1.02 |
|
P2rx3 | |
NM_145526 |
purinergic receptor P2X, ligand-gated ion channel, 3 (P2rx3), mRNA [NM_145526] |
KLA | .86 |
1.01 |
1.09 |
1.01 |
.99 |
1.10 |
1.14 |
| ATP | 1.03 |
.96 |
1.12 |
1.14 |
.96 |
1.03 |
.99 |
| KLA/ATP | .98 |
.99 |
1.09 |
1.10 |
1.04 |
1.06 |
1.00 |
|
P2rx4 | |
NM_011026 |
purinergic receptor P2X, ligand-gated ion channel 4 (P2rx4), mRNA [NM_011026] |
KLA | 1.43 |
1.51 |
1.72 |
1.88 |
2.11 |
2.56 |
3.11 |
| ATP | 1.00 |
.99 |
.85 |
.91 |
.93 |
1.13 |
1.98 |
| KLA/ATP | 1.50 |
1.53 |
1.43 |
1.30 |
1.22 |
1.81 |
3.72 |
|
P2rx5 | |
NM_033321 |
purinergic receptor P2X, ligand-gated ion channel, 5 (P2rx5), mRNA [NM_033321] |
KLA | 1.05 |
1.08 |
1.06 |
1.03 |
.99 |
.97 |
.99 |
| ATP | .92 |
.96 |
.94 |
.97 |
1.02 |
1.72 |
3.00 |
| KLA/ATP | 1.11 |
1.04 |
.98 |
.96 |
.98 |
1.39 |
2.14 |
|
P2rx6 | |
AK054195 |
2 days pregnant adult female oviduct cDNA, RIKEN full-length enriched library, clone:E230027A21 product:purinergic receptor P2X-like 1, orphan receptor, full insert sequence. [AK054195] |
KLA | .98 |
.97 |
1.02 |
1.01 |
1.03 |
1.01 |
.98 |
| ATP | 1.02 |
1.06 |
1.03 |
.95 |
1.05 |
.99 |
1.01 |
| KLA/ATP | .98 |
1.03 |
1.03 |
1.05 |
1.01 |
1.06 |
1.06 |
|
P2rx6 | |
NM_011028 |
purinergic receptor P2X, ligand-gated ion channel, 6 (P2rx6), mRNA [NM_011028] |
KLA | .91 |
.93 |
.99 |
1.00 |
.94 |
.87 |
.93 |
| ATP | .98 |
.97 |
1.05 |
.95 |
.96 |
.91 |
.93 |
| KLA/ATP | 1.03 |
.92 |
.99 |
.88 |
.89 |
.90 |
.88 |
|
P2rx7 | |
NM_011027 |
purinergic receptor P2X, ligand-gated ion channel, 7 (P2rx7), transcript variant 1, mRNA [NM_011027] |
KLA | .52 |
.52 |
.50 |
.59 |
.67 |
.98 |
.80 |
| ATP | .93 |
.87 |
1.11 |
.79 |
.57 |
.48 |
.52 |
| KLA/ATP | .50 |
.50 |
.63 |
.48 |
.87 |
.97 |
1.03 |
|
P2ry1 | |
NM_008772 |
purinergic receptor P2Y, G-protein coupled 1 (P2ry1), mRNA [NM_008772] |
KLA | .54 |
.54 |
.57 |
.48 |
.39 |
.36 |
.34 |
| ATP | 1.11 |
1.25 |
1.33 |
1.06 |
.83 |
.47 |
.41 |
| KLA/ATP | .57 |
.57 |
.70 |
.59 |
.54 |
.39 |
.36 |
|
P2ry10 | |
NM_172435 |
purinergic receptor P2Y, G-protein coupled 10 (P2ry10), mRNA [NM_172435] |
KLA | 1.24 |
1.28 |
1.23 |
1.17 |
1.16 |
1.08 |
1.04 |
| ATP | 1.02 |
1.16 |
1.29 |
1.47 |
1.29 |
1.27 |
1.07 |
| KLA/ATP | 1.29 |
1.40 |
1.57 |
1.68 |
1.28 |
1.24 |
1.27 |
|
P2ry13 | |
NM_028808 |
purinergic receptor P2Y, G-protein coupled 13 (P2ry13), mRNA [NM_028808] |
KLA | 2.34 |
2.64 |
4.05 |
3.58 |
3.00 |
1.98 |
.62 |
| ATP | 1.05 |
1.03 |
1.05 |
1.11 |
.86 |
.92 |
1.33 |
| KLA/ATP | 2.62 |
2.85 |
2.91 |
3.22 |
1.99 |
1.61 |
1.08 |
|
P2ry14 | |
NM_133200 |
purinergic receptor P2Y, G-protein coupled, 14 (P2ry14), transcript variant 1, mRNA [NM_133200] |
KLA | 4.59 |
4.87 |
6.13 |
6.05 |
5.35 |
4.97 |
2.90 |
| ATP | 1.06 |
1.01 |
1.24 |
1.40 |
1.09 |
1.74 |
2.28 |
| KLA/ATP | 4.62 |
5.16 |
5.79 |
7.03 |
5.62 |
4.44 |
4.76 |
|
P2ry2 | |
NM_008773 |
purinergic receptor P2Y, G-protein coupled 2 (P2ry2), mRNA [NM_008773] |
KLA | 1.57 |
1.53 |
1.38 |
1.67 |
2.02 |
1.28 |
2.44 |
| ATP | 1.00 |
1.01 |
1.04 |
1.96 |
4.55 |
3.46 |
2.23 |
| KLA/ATP | 1.63 |
1.52 |
1.43 |
2.61 |
4.20 |
2.42 |
2.17 |
|
P2ry4 | |
NM_020621 |
pyrimidinergic receptor P2Y, G-protein coupled, 4 (P2ry4), mRNA [NM_020621] |
KLA | 1.05 |
.98 |
1.01 |
.99 |
1.08 |
1.00 |
1.00 |
| ATP | .94 |
.98 |
.98 |
1.00 |
1.01 |
.95 |
1.06 |
| KLA/ATP | 1.02 |
.95 |
.90 |
1.01 |
.99 |
.99 |
1.00 |
|
P2ry5 | |
NM_175116 |
purinergic receptor P2Y, G-protein coupled, 5 (P2ry5), mRNA [NM_175116] |
KLA | .16 |
.17 |
.21 |
.19 |
.20 |
.33 |
.28 |
| ATP | 1.25 |
1.44 |
1.75 |
1.01 |
.54 |
1.08 |
.90 |
| KLA/ATP | .17 |
.17 |
.26 |
.27 |
.35 |
.49 |
.57 |
|
P2ry6 | |
NM_183168 |
pyrimidinergic receptor P2Y, G-protein coupled, 6 (P2ry6), mRNA [NM_183168] |
KLA | .50 |
.53 |
.58 |
.99 |
1.48 |
1.73 |
1.07 |
| ATP | .98 |
.99 |
.82 |
.69 |
.48 |
.54 |
1.39 |
| KLA/ATP | .48 |
.43 |
.35 |
.39 |
.46 |
.53 |
1.14 |
|
Pard3 | |
AK076429 |
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4832405A21 product:par-3 (partitioning defective 3) homolog (C. elegans), full insert sequence. [AK076429] |
KLA | .96 |
.96 |
1.03 |
.96 |
1.03 |
.99 |
1.19 |
| ATP | .97 |
.92 |
1.09 |
.99 |
1.00 |
1.03 |
.94 |
| KLA/ATP | .97 |
1.01 |
.97 |
1.05 |
.98 |
.92 |
1.04 |
|
Pard3 | |
NM_001013580 |
par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), transcript variant 2, mRNA [NM_001013580] |
KLA | 1.02 |
.99 |
1.03 |
.97 |
1.00 |
.97 |
1.04 |
| ATP | .93 |
1.02 |
.98 |
.95 |
1.02 |
1.02 |
.98 |
| KLA/ATP | 1.04 |
.98 |
1.01 |
.99 |
.96 |
.91 |
.95 |
|
Pard3 | |
NM_001013581 |
par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), transcript variant 1, mRNA [NM_001013581] |
KLA | .99 |
1.06 |
1.02 |
1.02 |
1.00 |
.98 |
.95 |
| ATP | .91 |
1.05 |
1.06 |
.99 |
1.04 |
.89 |
.99 |
| KLA/ATP | .98 |
.97 |
1.09 |
.97 |
1.01 |
.98 |
1.00 |
|
Pard3 | |
NM_001122850 |
par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), transcript variant 4, mRNA [NM_001122850] |
KLA | 1.01 |
.95 |
1.00 |
1.01 |
1.07 |
.91 |
.99 |
| ATP | 1.00 |
1.01 |
.98 |
.94 |
1.04 |
.98 |
1.00 |
| KLA/ATP | .99 |
.99 |
1.04 |
1.04 |
1.04 |
1.01 |
1.03 |
|
Pard3 | |
NM_033620 |
par-3 (partitioning defective 3) homolog (C. elegans) (Pard3), transcript variant 3, mRNA [NM_033620] |
KLA | .92 |
.93 |
.97 |
.96 |
1.00 |
.99 |
1.02 |
| ATP | 1.08 |
1.03 |
.93 |
.92 |
.99 |
.97 |
1.00 |
| KLA/ATP | .99 |
1.03 |
1.02 |
1.05 |
.96 |
1.06 |
1.03 |
|
Plg | |
NM_008877 |
plasminogen (Plg), mRNA [NM_008877] |
KLA | 1.02 |
1.05 |
1.06 |
1.02 |
1.01 |
1.09 |
1.07 |
| ATP | .99 |
.96 |
1.07 |
1.08 |
1.02 |
.95 |
1.09 |
| KLA/ATP | 1.09 |
.98 |
.98 |
1.09 |
1.21 |
1.08 |
1.04 |
|
Pomc | |
NM_008895 |
pro-opiomelanocortin-alpha (Pomc), mRNA [NM_008895] |
KLA | .94 |
.98 |
.99 |
1.06 |
1.09 |
1.45 |
1.61 |
| ATP | 1.11 |
1.02 |
1.19 |
1.14 |
.90 |
1.39 |
2.00 |
| KLA/ATP | 1.02 |
1.05 |
.94 |
1.20 |
1.14 |
1.53 |
2.62 |
|
Ppy | |
NM_008918 |
pancreatic polypeptide (Ppy), mRNA [NM_008918] |
KLA | .99 |
1.00 |
.94 |
1.04 |
.96 |
.95 |
.98 |
| ATP | .97 |
1.00 |
.99 |
.93 |
.97 |
1.00 |
.92 |
| KLA/ATP | .99 |
1.08 |
1.07 |
1.01 |
.97 |
1.00 |
1.07 |
|
Ppyr1 | |
AK035505 |
adult male urinary bladder cDNA, RIKEN full-length enriched library, clone:9530057L11 product:NEUROPEPTIDE Y RECEPTOR TYPE 4, full insert sequence [AK035505] |
KLA | .92 |
1.01 |
1.05 |
.97 |
1.03 |
1.03 |
1.03 |
| ATP | 1.06 |
1.00 |
1.01 |
1.06 |
.97 |
.81 |
.98 |
| KLA/ATP | 1.02 |
.95 |
1.05 |
1.12 |
1.16 |
1.14 |
.97 |
|
Prl | |
NM_011164 |
prolactin (Prl), mRNA [NM_011164] |
KLA | 1.01 |
1.00 |
1.06 |
1.02 |
1.05 |
.96 |
.97 |
| ATP | .99 |
1.02 |
.97 |
.98 |
.97 |
.95 |
1.00 |
| KLA/ATP | 1.00 |
1.01 |
1.00 |
.97 |
.96 |
.87 |
.95 |
|
Prlhr | |
NM_201615 |
prolactin releasing hormone receptor (Prlhr), mRNA [NM_201615] |
KLA | 1.04 |
1.01 |
1.03 |
1.06 |
1.05 |
1.14 |
1.13 |
| ATP | 1.03 |
.97 |
1.07 |
1.07 |
1.10 |
1.03 |
.98 |
| KLA/ATP | 1.05 |
1.04 |
1.05 |
1.03 |
.93 |
1.06 |
1.11 |
|
Prlr | |
AK083198 |
adult male hippocampus cDNA, RIKEN full-length enriched library, clone:C630026G18 product:unclassifiable, full insert sequence [AK083198] |
KLA | .99 |
1.07 |
1.00 |
.95 |
1.01 |
.90 |
1.01 |
| ATP | 1.02 |
.94 |
.97 |
1.00 |
.97 |
.94 |
.96 |
| KLA/ATP | .98 |
.94 |
.96 |
.96 |
.99 |
1.07 |
1.02 |
|
Prlr | |
AK087727 |
2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330012C04 product:hypothetical protein, full insert sequence [AK087727] |
KLA | 1.03 |
1.00 |
.99 |
1.01 |
1.02 |
1.04 |
.99 |
| ATP | 1.00 |
.95 |
1.13 |
1.06 |
.97 |
.98 |
1.04 |
| KLA/ATP | .97 |
1.01 |
.88 |
1.02 |
1.01 |
1.03 |
1.05 |
|
Prlr | |
NM_011169 |
prolactin receptor (Prlr), mRNA [NM_011169] |
KLA | .93 |
1.03 |
1.12 |
1.06 |
1.05 |
1.14 |
1.15 |
| ATP | .95 |
.99 |
1.11 |
1.13 |
1.06 |
1.19 |
1.18 |
| KLA/ATP | 1.02 |
1.01 |
1.05 |
1.10 |
1.10 |
1.21 |
1.07 |
|
Prss2 | |
NM_009430 |
protease, serine, 2 (Prss2), mRNA [NM_009430] |
KLA | .94 |
.99 |
.95 |
1.03 |
.89 |
1.08 |
1.06 |
| ATP | 1.04 |
.95 |
1.00 |
1.03 |
.96 |
.97 |
1.00 |
| KLA/ATP | 1.05 |
.96 |
1.01 |
1.05 |
1.00 |
1.11 |
1.11 |
|
Ptafr | |
AF004858 |
platelet activating factor receptor mRNA, partial cds. [AF004858] |
KLA | 1.20 |
1.24 |
1.22 |
1.15 |
1.15 |
1.23 |
1.40 |
| ATP | 1.03 |
1.05 |
1.04 |
1.19 |
1.37 |
1.33 |
1.63 |
| KLA/ATP | 1.28 |
1.33 |
1.17 |
1.25 |
1.29 |
1.50 |
1.90 |
|
Ptafr | |
NM_001081211 |
platelet-activating factor receptor (Ptafr), mRNA [NM_001081211] |
KLA | 1.73 |
1.73 |
1.60 |
1.31 |
1.61 |
1.84 |
2.08 |
| ATP | 1.06 |
1.10 |
.98 |
1.24 |
2.12 |
2.22 |
3.21 |
| KLA/ATP | 1.93 |
1.99 |
1.47 |
1.65 |
1.83 |
2.58 |
5.06 |
|
Ptgdr | |
NM_008962 |
prostaglandin D receptor (Ptgdr), mRNA [NM_008962] |
KLA | 1.04 |
1.01 |
1.01 |
1.01 |
1.01 |
1.02 |
.97 |
| ATP | 1.00 |
1.02 |
1.00 |
.99 |
.97 |
1.02 |
1.05 |
| KLA/ATP | .98 |
1.01 |
1.01 |
1.03 |
.99 |
1.01 |
.98 |
|
Ptger2 | |
NM_008964 |
prostaglandin E receptor 2 (subtype EP2) (Ptger2), mRNA [NM_008964] |
KLA | .84 |
.82 |
.77 |
.71 |
.68 |
.94 |
3.24 |
| ATP | 1.13 |
1.03 |
1.05 |
.80 |
3.49 |
4.06 |
3.47 |
| KLA/ATP | .90 |
.83 |
.76 |
.67 |
.86 |
2.21 |
4.62 |
|
Ptger3 | |
D17406 |
mRNA for prostaglandin E receptor EP3 subtype, complete cds [D17406] |
KLA | 1.04 |
.92 |
1.04 |
1.06 |
.98 |
.97 |
1.07 |
| ATP | .97 |
.96 |
1.06 |
.97 |
.99 |
.98 |
1.07 |
| KLA/ATP | 1.00 |
1.02 |
.98 |
1.00 |
1.01 |
1.05 |
.95 |
|
Ptger3 | |
NM_011196 |
prostaglandin E receptor 3 (subtype EP3) (Ptger3), mRNA [NM_011196] |
KLA | 1.06 |
1.00 |
1.01 |
.99 |
.97 |
.98 |
.93 |
| ATP | 1.00 |
.98 |
.94 |
.99 |
1.09 |
1.10 |
.97 |
| KLA/ATP | 1.01 |
1.02 |
.92 |
.96 |
1.07 |
1.30 |
1.08 |
|
Ptger4 | |
AK051137 |
12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130004L12 product:prostaglandin E receptor 4 (subtype EP4), full insert sequence. [AK051137] |
KLA | 1.01 |
1.08 |
.97 |
1.02 |
.99 |
.96 |
1.04 |
| ATP | .99 |
.99 |
.96 |
.98 |
.98 |
.94 |
.93 |
| KLA/ATP | 1.02 |
1.10 |
.97 |
1.04 |
1.03 |
.98 |
.93 |
|
Ptger4 | |
NM_008965 |
prostaglandin E receptor 4 (subtype EP4) (Ptger4), mRNA [NM_008965] |
KLA | 3.76 |
3.30 |
4.81 |
2.35 |
2.57 |
2.66 |
3.53 |
| ATP | 1.24 |
1.77 |
2.25 |
2.62 |
1.70 |
.84 |
.86 |
| KLA/ATP | 4.53 |
4.71 |
6.35 |
6.75 |
2.33 |
1.13 |
1.08 |
|
Ptgfr | |
AK086563 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930037F10 product:unclassifiable, full insert sequence [AK086563] |
KLA | 1.02 |
.98 |
1.02 |
.98 |
.99 |
.95 |
1.01 |
| ATP | .94 |
1.02 |
1.02 |
.96 |
1.04 |
1.00 |
.90 |
| KLA/ATP | 1.02 |
1.07 |
.99 |
.87 |
1.00 |
1.02 |
.96 |
|
Ptgfr | |
NM_008966 |
prostaglandin F receptor (Ptgfr), mRNA [NM_008966] |
KLA | 1.07 |
.96 |
.99 |
.99 |
.97 |
.97 |
.98 |
| ATP | .94 |
1.03 |
.98 |
1.00 |
1.03 |
1.05 |
1.10 |
| KLA/ATP | .95 |
.97 |
1.03 |
1.02 |
1.02 |
1.00 |
.99 |
|
Ptgir | |
NM_008967 |
prostaglandin I receptor (IP) (Ptgir), mRNA [NM_008967] |
KLA | .89 |
.94 |
1.08 |
1.86 |
2.47 |
1.66 |
2.03 |
| ATP | .98 |
.92 |
1.09 |
.96 |
3.20 |
5.46 |
1.68 |
| KLA/ATP | .83 |
.83 |
1.03 |
1.43 |
12.77 |
10.57 |
2.80 |
|
Pth | |
NM_020623 |
parathyroid hormone (Pth), mRNA [NM_020623] |
KLA | 1.03 |
1.04 |
.98 |
.99 |
1.01 |
1.06 |
1.00 |
| ATP | 1.04 |
1.00 |
.91 |
.97 |
1.00 |
1.07 |
1.07 |
| KLA/ATP | 1.02 |
.99 |
1.01 |
1.00 |
.99 |
1.02 |
1.05 |
|
Pth2r | |
NM_139270 |
parathyroid hormone 2 receptor (Pth2r), mRNA [NM_139270] |
KLA | .99 |
1.01 |
1.05 |
.98 |
.96 |
1.00 |
.99 |
| ATP | 1.00 |
.97 |
.97 |
1.01 |
.99 |
.98 |
.90 |
| KLA/ATP | 1.02 |
1.04 |
1.04 |
1.06 |
1.04 |
1.04 |
1.06 |
|
Pthr1 | |
NM_011199 |
parathyroid hormone receptor 1 (Pthr1), transcript variant 1, mRNA [NM_011199] |
KLA | .82 |
.90 |
.89 |
.94 |
.88 |
.86 |
.93 |
| ATP | 1.08 |
.95 |
.93 |
.89 |
.83 |
.86 |
.85 |
| KLA/ATP | .95 |
.87 |
.81 |
.86 |
.91 |
.93 |
.87 |
|
Pyy | |
NM_145435 |
peptide YY (Pyy), mRNA [NM_145435] |
KLA | 1.06 |
1.04 |
1.00 |
1.05 |
1.08 |
1.10 |
1.12 |
| ATP | 1.05 |
1.05 |
1.19 |
1.16 |
1.22 |
1.08 |
1.07 |
| KLA/ATP | 1.04 |
1.05 |
1.04 |
1.21 |
1.16 |
1.06 |
1.16 |
|
Rxfp1 | |
AK054129 |
2 days pregnant adult female oviduct cDNA, RIKEN full-length enriched library, clone:E230022G02 product:LEUCINE-RICH REPEAT-CONTAINING G PROTEIN-COUPLED RECEPTOR 7 homolog [Homo sapiens], full insert sequence. [AK054129] |
KLA | .99 |
1.03 |
.99 |
1.05 |
.99 |
1.03 |
1.01 |
| ATP | 1.01 |
1.01 |
.94 |
.95 |
.96 |
.95 |
1.06 |
| KLA/ATP | .98 |
1.01 |
1.05 |
.98 |
.92 |
.98 |
.99 |
|
Rxfp1 | |
NM_212452 |
relaxin/insulin-like family peptide receptor 1 (Rxfp1), mRNA [NM_212452] |
KLA | .83 |
.88 |
.88 |
.93 |
.98 |
.95 |
.98 |
| ATP | .96 |
.92 |
.95 |
.95 |
1.00 |
.96 |
.92 |
| KLA/ATP | .96 |
.90 |
.94 |
.92 |
.92 |
.96 |
.89 |
|
Rxfp2 | |
AK039086 |
adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230094D06 product:G protein-coupled receptor 106, full insert sequence. [AK039086] |
KLA | 1.05 |
1.06 |
1.00 |
1.01 |
.98 |
1.05 |
1.14 |
| ATP | 1.02 |
1.02 |
1.01 |
1.03 |
.96 |
1.08 |
1.03 |
| KLA/ATP | 1.01 |
.99 |
.96 |
1.00 |
.96 |
1.05 |
1.02 |
|
Rxfp2 | |
NM_080468 |
relaxin/insulin-like family peptide receptor 2 (Rxfp2), mRNA [NM_080468] |
KLA | 1.05 |
.97 |
1.03 |
1.08 |
1.06 |
1.03 |
.99 |
| ATP | .96 |
.95 |
.91 |
.96 |
.97 |
.94 |
.99 |
| KLA/ATP | 1.06 |
1.07 |
1.00 |
.95 |
.98 |
.97 |
.69 |
|
Sct | |
NM_011328 |
secretin (Sct), mRNA [NM_011328] |
KLA | 1.26 |
1.40 |
1.46 |
1.57 |
1.67 |
1.67 |
1.39 |
| ATP | .94 |
.96 |
1.00 |
1.03 |
1.03 |
1.00 |
1.11 |
| KLA/ATP | 1.31 |
1.41 |
1.24 |
1.22 |
1.18 |
1.20 |
1.23 |
|
Sctr | |
NM_001012322 |
secretin receptor (Sctr), mRNA [NM_001012322] |
KLA | .96 |
.94 |
1.01 |
1.01 |
1.02 |
.94 |
.99 |
| ATP | 1.06 |
.97 |
.99 |
.95 |
1.02 |
.99 |
.98 |
| KLA/ATP | 1.03 |
1.07 |
.99 |
1.07 |
.94 |
.99 |
1.00 |
|
Sst | |
NM_009215 |
somatostatin (Sst), mRNA [NM_009215] |
KLA | 1.07 |
1.09 |
1.12 |
1.14 |
1.11 |
1.12 |
1.11 |
| ATP | .99 |
.96 |
1.00 |
1.00 |
1.01 |
.99 |
1.03 |
| KLA/ATP | 1.08 |
1.04 |
1.13 |
1.04 |
1.07 |
1.07 |
1.10 |
|
Sstr1 | |
NM_009216 |
somatostatin receptor 1 (Sstr1), mRNA [NM_009216] |
KLA | .96 |
1.06 |
.98 |
1.03 |
.97 |
.95 |
.98 |
| ATP | .96 |
.99 |
1.04 |
.99 |
.97 |
.93 |
1.03 |
| KLA/ATP | .97 |
1.01 |
.99 |
1.03 |
.92 |
.94 |
1.09 |
|
Sstr3 | |
NM_009218 |
somatostatin receptor 3 (Sstr3), mRNA [NM_009218] |
KLA | 1.00 |
1.07 |
1.03 |
1.01 |
1.04 |
.99 |
1.01 |
| ATP | .99 |
.95 |
.98 |
1.06 |
.99 |
1.00 |
.98 |
| KLA/ATP | 1.06 |
.96 |
1.00 |
.92 |
.97 |
1.08 |
.99 |
|
Sstr4 | |
AK158660 |
visual cortex cDNA, RIKEN full-length enriched library, clone:K230047D01 product:unclassifiable, full insert sequence [AK158660] |
KLA | .98 |
.98 |
1.01 |
1.00 |
1.03 |
1.09 |
1.02 |
| ATP | .99 |
1.03 |
.98 |
1.05 |
.96 |
1.09 |
.99 |
| KLA/ATP | 1.02 |
1.01 |
.96 |
1.00 |
1.07 |
1.04 |
.98 |
|
Sstr4 | |
NM_009219 |
somatostatin receptor 4 (Sstr4), mRNA [NM_009219] |
KLA | 1.05 |
1.08 |
1.18 |
1.25 |
1.15 |
1.20 |
1.14 |
| ATP | 1.06 |
.99 |
1.19 |
1.31 |
1.31 |
1.14 |
1.06 |
| KLA/ATP | 1.15 |
1.19 |
1.46 |
1.29 |
1.27 |
1.27 |
1.17 |
|
Taar1 | |
NM_053205 |
trace amine-associated receptor 1 (Taar1), mRNA [NM_053205] |
KLA | 1.00 |
1.06 |
.96 |
1.05 |
1.01 |
.92 |
1.04 |
| ATP | 1.09 |
.89 |
.98 |
1.01 |
.96 |
.96 |
.95 |
| KLA/ATP | 1.05 |
1.02 |
1.08 |
.98 |
.91 |
.94 |
1.07 |
|
Taar2 | |
NM_001007266 |
trace amine-associated receptor 2 (Taar2), mRNA [NM_001007266] |
KLA | .91 |
.98 |
1.00 |
.96 |
.97 |
1.07 |
1.04 |
| ATP | 1.01 |
.95 |
.99 |
.92 |
.97 |
1.02 |
1.04 |
| KLA/ATP | 1.13 |
.95 |
.98 |
.86 |
.99 |
1.00 |
1.00 |
|
Taar4 | |
NM_001008499 |
trace amine-associated receptor 4 (Taar4), mRNA [NM_001008499] |
KLA | 1.03 |
.99 |
1.08 |
1.11 |
1.04 |
1.00 |
1.12 |
| ATP | .98 |
.95 |
.98 |
1.04 |
.98 |
1.10 |
1.07 |
| KLA/ATP | 1.03 |
1.09 |
1.11 |
1.07 |
.97 |
1.04 |
1.13 |
|
Taar9 | |
NM_001010831 |
trace amine-associated receptor 9 (Taar9), mRNA [NM_001010831] |
KLA | 1.05 |
1.09 |
1.08 |
1.13 |
1.15 |
1.12 |
1.04 |
| ATP | 1.01 |
1.04 |
1.03 |
1.07 |
1.07 |
1.15 |
1.06 |
| KLA/ATP | 1.23 |
1.10 |
1.12 |
1.04 |
1.04 |
1.07 |
1.05 |
|
Tac1 | |
AK015286 |
adult male testis cDNA, RIKEN full-length enriched library, clone:4930432H04 product:tachykinin 1, full insert sequence [AK015286] |
KLA | .98 |
1.08 |
1.00 |
.93 |
1.07 |
1.07 |
1.05 |
| ATP | 1.02 |
1.00 |
.97 |
1.07 |
1.00 |
1.10 |
1.01 |
| KLA/ATP | 1.05 |
1.01 |
.96 |
1.04 |
.98 |
1.12 |
1.03 |
|
Tac1 | |
NM_009311 |
tachykinin 1 (Tac1), mRNA [NM_009311] |
KLA | .99 |
1.03 |
1.07 |
1.03 |
1.02 |
1.10 |
1.18 |
| ATP | 1.00 |
1.01 |
1.05 |
1.10 |
1.02 |
1.06 |
1.08 |
| KLA/ATP | 1.06 |
.96 |
1.01 |
1.13 |
1.13 |
1.08 |
.97 |
|
Tac2 | |
D14423 |
PPT-B mRNA for preprotachykinin B, complete cds [D14423] |
KLA | 1.21 |
1.22 |
1.16 |
1.20 |
1.10 |
1.12 |
1.12 |
| ATP | .99 |
1.00 |
1.09 |
1.09 |
1.13 |
1.11 |
.96 |
| KLA/ATP | 1.12 |
1.29 |
1.30 |
1.31 |
1.21 |
1.13 |
.97 |
|
Tac4 | |
NM_053093 |
tachykinin 4 (Tac4), mRNA [NM_053093] |
KLA | .91 |
.95 |
.98 |
.98 |
.95 |
1.02 |
.94 |
| ATP | 1.01 |
.96 |
.92 |
.98 |
.98 |
.99 |
.96 |
| KLA/ATP | .94 |
.94 |
.97 |
1.04 |
.92 |
.96 |
.98 |
|
Tacr1 | |
NM_009313 |
tachykinin receptor 1 (Tacr1), mRNA [NM_009313] |
KLA | 1.21 |
1.16 |
1.23 |
1.08 |
1.14 |
1.12 |
1.06 |
| ATP | 1.05 |
1.03 |
1.06 |
1.01 |
1.00 |
1.02 |
1.09 |
| KLA/ATP | 1.16 |
1.23 |
1.06 |
1.22 |
1.10 |
1.07 |
1.08 |
|
Tacr2 | |
NM_009314 |
tachykinin receptor 2 (Tacr2), mRNA [NM_009314] |
KLA | 1.04 |
1.13 |
1.11 |
1.14 |
1.12 |
1.11 |
1.06 |
| ATP | 1.02 |
1.00 |
1.01 |
1.03 |
1.05 |
1.10 |
1.01 |
| KLA/ATP | 1.05 |
1.10 |
1.17 |
1.17 |
1.06 |
1.01 |
1.03 |
|
Tacr3 | |
NM_021382 |
tachykinin receptor 3 (Tacr3), mRNA [NM_021382] |
KLA | .97 |
.98 |
1.07 |
1.00 |
1.01 |
1.02 |
.92 |
| ATP | 1.01 |
.99 |
.99 |
1.01 |
1.02 |
1.01 |
1.05 |
| KLA/ATP | 1.03 |
1.00 |
1.02 |
1.01 |
.94 |
1.01 |
1.00 |
|
Tbxa2r | |
NM_009325 |
thromboxane A2 receptor (Tbxa2r), mRNA [NM_009325] |
KLA | 1.02 |
1.02 |
1.03 |
1.01 |
1.01 |
1.02 |
1.05 |
| ATP | .97 |
.98 |
1.03 |
1.09 |
1.06 |
1.09 |
1.01 |
| KLA/ATP | 1.00 |
1.05 |
1.02 |
1.04 |
1.09 |
1.14 |
1.12 |
|
Thra | |
NM_178060 |
thyroid hormone receptor alpha (Thra), mRNA [NM_178060] |
KLA | .55 |
.54 |
.56 |
.60 |
.79 |
.88 |
.82 |
| ATP | 1.05 |
.92 |
.81 |
.73 |
1.60 |
1.17 |
.99 |
| KLA/ATP | .53 |
.53 |
.54 |
.64 |
3.05 |
1.91 |
1.34 |
|
Thrb | |
NM_009380 |
thyroid hormone receptor beta (Thrb), transcript variant 2, mRNA [NM_009380] |
KLA | .99 |
.97 |
1.00 |
1.00 |
.98 |
1.03 |
1.01 |
| ATP | .99 |
1.02 |
1.01 |
.99 |
.99 |
.96 |
1.03 |
| KLA/ATP | .97 |
1.00 |
.97 |
1.03 |
1.01 |
.96 |
1.01 |
|
Trh | |
NM_009426 |
thyrotropin releasing hormone (Trh), mRNA [NM_009426] |
KLA | 1.07 |
1.04 |
1.05 |
.97 |
1.03 |
.95 |
.98 |
| ATP | .94 |
1.09 |
1.01 |
.97 |
.96 |
1.08 |
.96 |
| KLA/ATP | .92 |
.99 |
1.08 |
.98 |
1.00 |
1.02 |
.94 |
|
Trhr | |
NM_013696 |
thyrotropin releasing hormone receptor (Trhr), mRNA [NM_013696] |
KLA | 1.02 |
1.02 |
1.03 |
1.02 |
.97 |
.96 |
.95 |
| ATP | 1.07 |
.94 |
.98 |
1.01 |
.99 |
.99 |
.96 |
| KLA/ATP | 1.02 |
.99 |
.99 |
1.00 |
.99 |
.94 |
.94 |
|
Trhr2 | |
NM_133202 |
thyrotropin releasing hormone receptor 2 (Trhr2), mRNA [NM_133202] |
KLA | .99 |
1.01 |
1.00 |
1.02 |
.98 |
1.07 |
1.08 |
| ATP | .96 |
1.02 |
1.01 |
1.02 |
.95 |
.97 |
.98 |
| KLA/ATP | 1.01 |
.96 |
1.00 |
1.04 |
.97 |
1.00 |
.97 |
|
Tshb | |
AK036251 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630048K15 product:thyroid stimulating hormone, beta subunit, full insert sequence [AK036251] |
KLA | .98 |
.97 |
.97 |
1.05 |
.92 |
.98 |
1.00 |
| ATP | .99 |
.92 |
.96 |
1.02 |
1.01 |
1.02 |
.97 |
| KLA/ATP | .99 |
.98 |
1.03 |
.99 |
.96 |
1.00 |
1.03 |
|
Tshb | |
NM_009432 |
thyroid stimulating hormone, beta subunit (Tshb), mRNA [NM_009432] |
KLA | 1.00 |
1.06 |
1.07 |
1.05 |
.98 |
1.03 |
.99 |
| ATP | 1.03 |
1.01 |
1.01 |
.93 |
1.01 |
.97 |
1.00 |
| KLA/ATP | 1.00 |
1.01 |
.98 |
.95 |
1.01 |
1.08 |
.95 |
|
Tshr | |
NM_011648 |
thyroid stimulating hormone receptor (Tshr), transcript variant 1, mRNA [NM_011648] |
KLA | 1.01 |
.99 |
1.02 |
1.01 |
1.00 |
1.01 |
.97 |
| ATP | 1.05 |
1.01 |
1.01 |
.97 |
.99 |
.99 |
1.05 |
| KLA/ATP | .97 |
1.05 |
1.02 |
.95 |
.97 |
.93 |
.99 |
|
Tspo | |
NM_009775 |
translocator protein (Tspo), mRNA [NM_009775] |
KLA | 2.43 |
2.59 |
2.88 |
3.03 |
4.05 |
4.37 |
4.80 |
| ATP | 1.15 |
1.16 |
.97 |
1.30 |
1.13 |
1.25 |
2.08 |
| KLA/ATP | 2.72 |
2.79 |
2.51 |
3.45 |
2.78 |
3.22 |
5.46 |
|
Ucn2 | |
AF331517 |
urocortin II mRNA, complete cds [AF331517] |
KLA | 1.04 |
.99 |
1.03 |
1.00 |
1.01 |
1.04 |
.98 |
| ATP | 1.04 |
1.13 |
1.01 |
1.11 |
1.06 |
1.10 |
1.01 |
| KLA/ATP | 1.01 |
.97 |
1.05 |
1.13 |
1.08 |
.91 |
1.07 |
|
Ucn3 | |
NM_031250 |
urocortin 3 (Ucn3), mRNA [NM_031250] |
KLA | .99 |
.92 |
1.06 |
.98 |
.97 |
1.01 |
1.00 |
| ATP | .98 |
1.04 |
1.00 |
1.05 |
.99 |
.99 |
.93 |
| KLA/ATP | 1.10 |
1.04 |
1.03 |
1.00 |
1.01 |
1.03 |
.99 |
|
Uts2 | |
NM_011910 |
urotensin 2 (Uts2), mRNA [NM_011910] |
KLA | 1.01 |
1.08 |
1.07 |
.97 |
.97 |
1.00 |
1.13 |
| ATP | .98 |
.99 |
1.02 |
1.02 |
.96 |
1.01 |
1.00 |
| KLA/ATP | .99 |
.96 |
1.03 |
1.04 |
.95 |
.97 |
.99 |
|
Uts2r | |
NM_145440 |
urotensin 2 receptor (Uts2r), mRNA [NM_145440] |
KLA | 1.19 |
1.22 |
1.18 |
1.33 |
1.24 |
1.15 |
1.06 |
| ATP | 1.06 |
1.19 |
1.74 |
2.18 |
1.33 |
.97 |
1.03 |
| KLA/ATP | 1.19 |
1.28 |
1.88 |
2.05 |
1.49 |
1.12 |
1.20 |
|
Vip | |
NM_011702 |
vasoactive intestinal polypeptide (Vip), mRNA [NM_011702] |
KLA | 1.02 |
.93 |
.96 |
1.07 |
1.01 |
1.01 |
1.03 |
| ATP | .99 |
.98 |
.99 |
1.00 |
1.05 |
.99 |
1.02 |
| KLA/ATP | 1.11 |
.98 |
.94 |
1.03 |
1.01 |
.99 |
.98 |
|
Vipr1 | |
NM_011703 |
vasoactive intestinal peptide receptor 1 (Vipr1), mRNA [NM_011703] |
KLA | 1.00 |
1.03 |
1.06 |
1.03 |
.99 |
1.00 |
.88 |
| ATP | 1.03 |
.95 |
1.12 |
1.03 |
.98 |
1.02 |
.89 |
| KLA/ATP | .99 |
1.04 |
1.09 |
1.04 |
1.00 |
.96 |
.85 |
|
Vipr2 | |
AK038743 |
adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230059F17 product:vasoactive intestinal peptide receptor 2, full insert sequence. [AK038743] |
KLA | 1.01 |
1.03 |
1.00 |
.95 |
1.08 |
1.08 |
.97 |
| ATP | .99 |
1.01 |
.98 |
.95 |
1.03 |
.98 |
.96 |
| KLA/ATP | 1.03 |
1.05 |
1.03 |
1.03 |
1.01 |
1.07 |
1.05 |
|
Vipr2 | |
NM_009511 |
vasoactive intestinal peptide receptor 2 (Vipr2), mRNA [NM_009511] |
KLA | 1.02 |
.98 |
1.05 |
.99 |
1.01 |
1.06 |
1.05 |
| ATP | .96 |
.99 |
1.03 |
1.04 |
1.02 |
1.07 |
.92 |
| KLA/ATP | 1.07 |
1.04 |
.97 |
1.10 |
1.02 |
1.13 |
1.02 |
|